📚 Additional Documentation

Deep Research Bioreason

(GAPDH-deep-research-bioreason.md)

BioReason Chat Export

Exported on March 22, 2026 at 03:07 AM

Organism: Homo sapiens

Sequence:

MGKVKVGVNGFGRIGRLVTRAAFNSGKVDIVAINDPFIDLNYMVYMFQYDSTHGKFHGTVKAENGKLVINGNPITIFQERDPSKIKWGDAGAEYVVESTGVFTTMEKAGAHLQGGAKRVIISAPSADAPMFVMGVNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHAITATQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTANVSVVDLTCRLEKPAKYDDIKKVVKQASEGPLKGILGYTEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVKLISWYDNEFGYSNRVVDLMAHMASKE

Thinking Trace

I begin with the InterPro architecture. The polypeptide carries two broad family signatures that define its identity: IPR020831 (Glyceraldehyde/Erythrose phosphate dehydrogenase family, residues 3–334) and IPR006424 (Glyceraldehyde-3-phosphate dehydrogenase, type I family, residues 5–326). These envelop an N-terminal dinucleotide-binding module and a C-terminal catalytic core. Specifically, the N-terminus contains IPR020828 (Glyceraldehyde 3-phosphate dehydrogenase, NAD(P) binding domain, residues 4–152), nested within the broader IPR036291 (NAD(P)-binding domain superfamily, residues 4–173). This Rossmann-like fold dictates tight binding of oxidized/reduced nicotinamide cofactors and positions the adenine-ribose-phosphate moiety for hydride transfer. The C-terminal half is defined by IPR020829 (Glyceraldehyde 3-phosphate dehydrogenase, catalytic domain, residues 157–314), which houses the chemistry-bearing residues. IPR020830 pinpoints the active site (Glyceraldehyde 3-phosphate dehydrogenase, active site, residues 150–157), a conserved motif that stabilizes reaction intermediates and couples substrate turnover to cofactor redox state. The ordered arrangement—N-terminal NAD-binding domain feeding a C-terminal catalytic barrel—creates a soluble, tetramer-prone oxidoreductase scaffold characteristic of type I GAPDH enzymes.

This architecture causes a specific molecular function: a nicotinamide-dependent dehydrogenase that acts on a secondary alcohol/aldehyde substrate through an NAD(H)-coupled pathway. The NAD(P)-binding module and catalytic domain together necessitate GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor. The presence of a canonical GAPDH catalytic site and type I family membership further indicate substrate preference for glyceraldehyde-3-phosphate and inorganic phosphate, consistent with classical aldehyde dehydrogenase chemistry and acyl-phosphate formation.

From this molecular activity, the biological process follows. In human cells, such a reaction integrates into central carbon flux, funneling triose phosphates toward energy and biosynthesis. Therefore, the enzyme feeds into carbohydrate breakdown and energy metabolism; the most parsimonious process assignment is carbohydrate metabolic process (GO:0005975), with a mechanistic emphasis on redox-driven steps that couple to ATP generation and reductant balance.

The cellular component and subcellular location are implied by solubility and domain composition. The absence of transmembrane segments and the soluble Rossmann/catalytic core architecture point to a cytosolic enzyme. This aligns with a cytoplasmic localization, formalized as GO:0005737 cytoplasm, where glycolytic enzymes assemble and exchange metabolites.

Mechanistically, I hypothesize a homotetrameric oxidoreductase that binds NAD+ via its N-terminal Rossmann-like domain, positions the phosphate-bearing substrate in the catalytic pocket, and executes a NAD-dependent hydride transfer that generates an acyl-phosphate intermediate before phosphate-dependent rearrangement. In human cells, such a cytosolic dehydrogenase likely forms transient assemblies with other glycolytic enzymes to channel intermediates efficiently. Thus, probable partners include upstream and downstream glycolytic nodes and scaffolds that organize carbohydrate flux in the cytoplasm.

Functional Summary

A soluble cytoplasmic oxidoreductase that uses a nicotinamide-binding module to couple NAD-dependent redox chemistry to aldehyde- and phosphate-handling steps within central carbon metabolism. It assembles as a soluble dehydrogenase that channels triose-phosphate intermediates through a catalytic core to support energy and biosynthetic pathways in the cytoplasm, functioning as a NAD-linked hub that integrates carbohydrate breakdown with cellular energy balance.

UniProt Summary

Probable glyceraldehyde-3-phosphate dehydrogenase.

InterPro Domains

Glyceraldehyde/Erythrose phosphate dehydrogenase family (IPR020831, family) — residues 3-334
Glyceraldehyde 3-phosphate dehydrogenase, NAD(P) binding domain (IPR020828, domain) — residues 4-152
NAD(P)-binding domain superfamily (IPR036291, homologous_superfamily) — residues 4-173
Glyceraldehyde-3-phosphate dehydrogenase, type I (IPR006424, family) — residues 5-326
Glyceraldehyde 3-phosphate dehydrogenase, active site (IPR020830, active_site) — residues 150-157
Glyceraldehyde 3-phosphate dehydrogenase, catalytic domain (IPR020829, domain) — residues 157-314

GO Terms

Molecular Function: molecular_function (GO:0003674), binding (GO:0005488), molecular function regulator activity (GO:0098772), enzyme regulator activity (GO:0030234), protein binding (GO:0005515), molecular function inhibitor activity (GO:0140678), identical protein binding (GO:0042802), protein domain specific binding (GO:0019904), peptidase regulator activity (GO:0061134), enzyme inhibitor activity (GO:0004857), endopeptidase regulator activity (GO:0061135), peptidase inhibitor activity (GO:0030414), disordered domain specific binding (GO:0097718), endopeptidase inhibitor activity (GO:0004866)

Biological Process: biological_process (GO:0008150), positive regulation of biological process (GO:0048518), regulation of biological process (GO:0050789), biological process involved in interspecies interaction between organisms (GO:0044419), immune system process (GO:0002376), biological regulation (GO:0065007), response to stimulus (GO:0050896), cellular process (GO:0009987), negative regulation of biological process (GO:0048519), response to external stimulus (GO:0009605), positive regulation of signaling (GO:0023056), response to chemical (GO:0042221), positive regulation of response to stimulus (GO:0048584), regulation of metabolic process (GO:0019222), immune response (GO:0006955), positive regulation of multicellular organismal process (GO:0051240), regulation of multicellular organismal process (GO:0051239), negative regulation of metabolic process (GO:0009892), response to biotic stimulus (GO:0009607), regulation of cellular process (GO:0050794), regulation of response to stimulus (GO:0048583), positive regulation of metabolic process (GO:0009893), cellular response to stimulus (GO:0051716), regulation of signaling (GO:0023051), regulation of molecular function (GO:0065009), response to stress (GO:0006950), negative regulation of cellular process (GO:0048523), response to other organism (GO:0051707), positive regulation of cellular process (GO:0048522), positive regulation of signal transduction (GO:0009967), regulation of catalytic activity (GO:0050790), negative regulation of nitrogen compound metabolic process (GO:0051172), response to external biotic stimulus (GO:0043207), positive regulation of macromolecule metabolic process (GO:0010604), negative regulation of molecular function (GO:0044092), regulation of signal transduction (GO:0009966), defense response (GO:0006952), regulation of macromolecule metabolic process (GO:0060255), regulation of cytokine production (GO:0001817), negative regulation of cellular metabolic process (GO:0031324), response to organic substance (GO:0010033), innate immune response (GO:0045087), defense response to other organism (GO:0098542), regulation of catabolic process (GO:0009894), regulation of cell communication (GO:0010646), cellular response to chemical stimulus (GO:0070887), negative regulation of macromolecule metabolic process (GO:0010605), humoral immune response (GO:0006959), regulation of biosynthetic process (GO:0009889), regulation of nitrogen compound metabolic process (GO:0051171), positive regulation of cell communication (GO:0010647), regulation of cellular metabolic process (GO:0031323), negative regulation of biosynthetic process (GO:0009890), positive regulation of cytokine production (GO:0001819), regulation of primary metabolic process (GO:0080090), antimicrobial humoral response (GO:0019730), negative regulation of catalytic activity (GO:0043086), response to cytokine (GO:0034097), regulation of macromolecule biosynthetic process (GO:0010556), regulation of protein metabolic process (GO:0051246), cellular response to organic substance (GO:0071310), regulation of hydrolase activity (GO:0051336), negative regulation of protein metabolic process (GO:0051248), regulation of autophagy (GO:0010506), positive regulation of gene expression (GO:0010628), regulation of gene expression (GO:0010468), regulation of type I interferon production (GO:0032479), regulation of amide metabolic process (GO:0034248), positive regulation of type I interferon production (GO:0032481), regulation of cellular biosynthetic process (GO:0031326), positive regulation of intracellular signal transduction (GO:1902533), negative regulation of macromolecule biosynthetic process (GO:0010558), negative regulation of cellular biosynthetic process (GO:0031327), response to type II interferon (GO:0034341), regulation of cellular catabolic process (GO:0031329), negative regulation of gene expression (GO:0010629), regulation of intracellular signal transduction (GO:1902531), negative regulation of amide metabolic process (GO:0034249), negative regulation of translation (GO:0017148), negative regulation of hydrolase activity (GO:0051346), regulation of proteolysis (GO:0030162), regulation of macroautophagy (GO:0016241), antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844), regulation of peptidase activity (GO:0052547), cellular response to cytokine stimulus (GO:0071345), regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043122), regulation of cellular macromolecule biosynthetic process (GO:2000112), positive regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043123), regulation of translation (GO:0006417), negative regulation of proteolysis (GO:0045861), cellular response to type II interferon (GO:0071346), negative regulation of cellular macromolecule biosynthetic process (GO:2000113), post-transcriptional regulation of gene expression (GO:0010608), regulation of endopeptidase activity (GO:0052548), negative regulation of peptidase activity (GO:0010466), negative regulation of endopeptidase activity (GO:0010951)

Cellular Component: cellular_component (GO:0005575), cellular anatomical entity (GO:0110165), intracellular anatomical structure (GO:0005622), organelle (GO:0043226), envelope (GO:0031975), membrane (GO:0016020), cytosol (GO:0005829), cell periphery (GO:0071944), cytoplasm (GO:0005737), endomembrane system (GO:0012505), organelle membrane (GO:0031090), organelle envelope (GO:0031967), nuclear envelope (GO:0005635), intracellular organelle (GO:0043229), membrane-bounded organelle (GO:0043227), plasma membrane (GO:0005886), nuclear membrane (GO:0031965), intracellular membrane-bounded organelle (GO:0043231), nucleus (GO:0005634)

Generated by BioReason

Deep Research Bioreason Rl

(GAPDH-deep-research-bioreason-rl.md)

BioReason Chat Export

Exported on March 22, 2026 at 03:07 AM

Organism: Homo sapiens

Sequence:

MGKVKVGVNGFGRIGRLVTRAAFNSGKVDIVAINDPFIDLNYMVYMFQYDSTHGKFHGTVKAENGKLVINGNPITIFQERDPSKIKWGDAGAEYVVESTGVFTTMEKAGAHLQGGAKRVIISAPSADAPMFVMGVNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHAITATQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTANVSVVDLTCRLEKPAKYDDIKKVVKQASEGPLKGILGYTEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVKLISWYDNEFGYSNRVVDLMAHMASKE

Thinking Trace

Functional Summary

UniProt Summary

Probable glyceraldehyde-3-phosphate dehydrogenase.

InterPro Domains

Glyceraldehyde/Erythrose phosphate dehydrogenase family (IPR020831, family) — residues 3-334
Glyceraldehyde 3-phosphate dehydrogenase, NAD(P) binding domain (IPR020828, domain) — residues 4-152
NAD(P)-binding domain superfamily (IPR036291, homologous_superfamily) — residues 4-173
Glyceraldehyde-3-phosphate dehydrogenase, type I (IPR006424, family) — residues 5-326
Glyceraldehyde 3-phosphate dehydrogenase, active site (IPR020830, active_site) — residues 150-157
Glyceraldehyde 3-phosphate dehydrogenase, catalytic domain (IPR020829, domain) — residues 157-314

GO Terms

Generated by BioReason

Deep Research Perplexity

(GAPDH-deep-research-perplexity.md)

provider: perplexity
model: sonar-deep-research
cached: false
start_time: '2025-12-29T11:47:09.007674'
end_time: '2025-12-29T11:49:41.604644'
duration_seconds: 152.6
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: GAPDH
gene_symbol: GAPDH
uniprot_accession: P04406
protein_description: 'RecName: Full=Glyceraldehyde-3-phosphate dehydrogenase {ECO:0000303|PubMed:6096136};
Short=GAPDH {ECO:0000303|PubMed:2987855}; EC=1.2.1.12 {ECO:0000269|PubMed:3170585};
AltName: Full=Peptidyl-cysteine S-nitrosylase GAPDH {ECO:0000305}; EC=2.6.99.-
{ECO:0000250|UniProtKB:P04797};'
gene_info: Name=GAPDH {ECO:0000303|PubMed:2987855, ECO:0000312|HGNC:HGNC:4141};
Synonyms=GAPD {ECO:0000303|PubMed:6096136}; ORFNames=CDABP0047, OK/SW-cl.12;
organism_full: Homo sapiens (Human).
protein_family: Belongs to the glyceraldehyde-3-phosphate dehydrogenase
protein_domains: GlycerAld/Erythrose_P_DH. (IPR020831); GlycerAld_3-P_DH_AS. (IPR020830);
GlycerAld_3-P_DH_cat. (IPR020829); GlycerAld_3-P_DH_NAD(P)-bd. (IPR020828); Glyceraldehyde-3-P_DH_1.
(IPR006424)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
reasoning_effort: medium
search_domain_filter: []
return_citations: true
temperature: 0.0
citation_count: 58

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

UniProt Accession: P04406
Protein Description: RecName: Full=Glyceraldehyde-3-phosphate dehydrogenase {ECO:0000303|PubMed:6096136}; Short=GAPDH {ECO:0000303|PubMed:2987855}; EC=1.2.1.12 {ECO:0000269|PubMed:3170585}; AltName: Full=Peptidyl-cysteine S-nitrosylase GAPDH {ECO:0000305}; EC=2.6.99.- {ECO:0000250|UniProtKB:P04797};
Gene Information: Name=GAPDH {ECO:0000303|PubMed:2987855, ECO:0000312|HGNC:HGNC:4141}; Synonyms=GAPD {ECO:0000303|PubMed:6096136}; ORFNames=CDABP0047, OK/SW-cl.12;
Organism (full): Homo sapiens (Human).
Protein Family: Belongs to the glyceraldehyde-3-phosphate dehydrogenase
Key Domains: GlycerAld/Erythrose_P_DH. (IPR020831); GlycerAld_3-P_DH_AS. (IPR020830); GlycerAld_3-P_DH_cat. (IPR020829); GlycerAld_3-P_DH_NAD(P)-bd. (IPR020828); Glyceraldehyde-3-P_DH_1. (IPR006424)

MANDATORY VERIFICATION STEPS:

Check if the gene symbol "GAPDH" matches the protein description above
Verify the organism is correct: Homo sapiens (Human).
Check if protein family/domains align with what you find in literature
If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'GAPDH' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene GAPDH (gene ID: GAPDH, UniProt: P04406) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

This is a comprehensive request for a research report on the GAPDH gene (P04406 from UniProt, human). The user has provided extensive search results and wants me to create a detailed, well-cited research report following the specified formatting rules.

Let me break down what I need to do:
1. Verify I'm researching the correct gene - GAPDH, P04406, from Homo sapiens
2. Create a 10,000+ word report in scientific format
3. Focus on: primary function, substrate specificity, cellular localization, biochemical/signaling pathways
4. Properly cite all claims using the search results provided
5. Follow strict formatting rules (no lists, multiple paragraphs per section, proper headers)
6. Prioritize experimental evidence and precise studies

From the search results provided, I have extensive information about GAPDH covering:
- Its classical metabolic function in glycolysis (step 6)
- Its non-metabolic functions (transcription, apoptosis, transport, DNA repair)
- Post-translational modifications (S-nitrosylation, phosphorylation, acetylation, etc.)
- Subcellular localization (cytoplasm, nucleus, mitochondria, vesicles)
- Clinical significance in cancer, neurodegenerative diseases, diabetes
- Structure and mechanism
- Multiple moonlighting functions

I'll organize this into major sections covering:
1. Title and summary
2. Overview and structure
3. Primary metabolic function
4. Catalytic mechanism
5. Non-metabolic/moonlighting functions
6. Post-translational modifications and regulation
7. Subcellular localization and distribution
8. Clinical and disease significance
9. Therapeutic potential
10. Conclusion

Let me now write the comprehensive report following all the formatting guidelines.

Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH): A Multifunctional Enzyme Integrating Metabolism, Signaling, and Cellular Homeostasis

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) represents one of the most remarkable examples of protein moonlighting in contemporary cell biology, serving as both an indispensable glycolytic enzyme and a critical regulator of cellular stress response, apoptosis, DNA repair, and metabolic switching[1]. This approximately 37-kilodalton enzyme catalyzes the sixth step of glycolysis, converting glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate while generating the critical reducing cofactor nicotinamide adenine dinucleotide (NADH)[1][2]. However, beyond this well-established metabolic role, GAPDH participates in numerous non-metabolic processes including transcriptional regulation, apoptosis initiation, endoplasmic reticulum-to-Golgi vesicle shuttling, rapid axonal transport, heme homeostasis, DNA damage repair, and antimicrobial defense[1][7][8][19][20][22][25]. The functional diversity of GAPDH is intimately linked to its complex post-translational modifications, dynamic subcellular localization, and ability to form specific protein-protein interactions that are regulated by cellular stress and metabolic status. This comprehensive report synthesizes current knowledge regarding GAPDH's structure, catalytic mechanism, multifunctional roles, regulatory mechanisms, and pathophysiological significance in human disease states.

Structural Organization and Oligomerization State

GAPDH exists as a highly conserved 335-amino acid polypeptide that exhibits extraordinary structural organization critical to both its catalytic and non-catalytic functions[1][31]. The protein is organized into two functionally distinct domains: the NAD+ binding domain comprising amino acids 1 to 150, which adopts the classical Rossmann fold structure characteristic of nucleotide-binding proteins, and the catalytic domain extending from amino acids 151 to 335, which contains the active site with the critical catalytic cysteine residue[31][42]. Under physiological conditions, cytoplasmic GAPDH exists predominantly as a homodimer of dimers, forming a tetrameric quaternary structure composed of four identical 37-kilodalton subunits[1][9]. This tetrameric organization is not merely a passive state but rather represents the catalytically active form of the enzyme, and the association-dissociation dynamics of these subunits serve as a regulatory mechanism that controls both glycolytic activity and the capacity to engage in non-metabolic functions[36][49]. Each subunit contains a single catalytic thiol group that is critical for enzymatic activity, and this cysteine residue is remarkably redox-sensitive, making it susceptible to oxidative and nitrosative modifications that serve as cellular stress sensors[1][8][11][26].

The architectural integrity of the GAPDH tetramer is maintained through specific interactions at both the dimer interface and tetramer interface, with residues such as threonine 229 serving as critical structural determinants[49]. Recent structural studies employing crystallography, small-angle X-ray scattering, and mass spectrometry have demonstrated that the dimer and tetramer interfaces are not merely structural scaffolds but rather represent functional domains that participate in RNA binding and regulate the enzyme's ability to engage with other cellular proteins[49]. The NAD+ binding domain itself contains a conserved histidine residue involved in heme binding and is also responsible for interaction with various cellular RNAs and protein partners[15][31]. Notably, nuclear GAPDH exhibits an increased isoelectric point relative to cytoplasmic GAPDH, suggesting that post-translational modifications or protein conformational changes may accompany nuclear localization[1]. The structural plasticity of GAPDH, particularly its capacity to undergo conformational changes in response to post-translational modifications and interactions with regulatory proteins, represents a key mechanism through which a single polypeptide can execute such diverse cellular functions.

Primary Metabolic Function: Glycolytic Catalysis

The classical and best-characterized function of GAPDH is the catalysis of the oxidative phosphorylation of glyceraldehyde-3-phosphate (G3P), the sixth step of glycolysis[1][2][13]. In this reaction, GAPDH catalyzes the coupled oxidation and phosphorylation of glyceraldehyde-3-phosphate in the presence of inorganic phosphate (Pi) and the coenzyme nicotinamide adenine dinucleotide (NAD+), producing 1,3-bisphosphoglycerate (1,3-BPG), the reduced cofactor NADH, and a free proton[1][2][5]. This reaction is thermodynamically coupled to the subsequent phosphorylation step catalyzed by phosphoglycerate kinase, allowing the unfavorable phosphorylation reaction to proceed by coupling it to the favorable oxidation reaction[1][13]. From a metabolic perspective, the GAPDH-catalyzed reaction represents the first step in glycolysis that generates reducing equivalents in the form of NADH, which are subsequently utilized in the electron transport chain to produce approximately three molecules of adenosine triphosphate (ATP) per NADH generated[13][32]. Furthermore, the 1,3-bisphosphoglycerate product contains a high-energy acyl phosphate bond that is subsequently transferred to ADP by phosphoglycerate kinase to yield one ATP molecule through substrate-level phosphorylation[13][32]. Since glycolysis breaks one glucose molecule into two molecules of glyceraldehyde-3-phosphate, the GAPDH reaction operates twice per glucose molecule, resulting in the generation of two NADH molecules and setting the stage for two ATP molecules of substrate-level phosphorylation[13][32].

The GAPDH-catalyzed reaction is not reversible under physiological conditions due to the large negative free energy change associated with the coupling of oxidation to phosphorylation[1]. This essentially unidirectional catalysis in the glycolytic direction is critical for maintaining the metabolic flux through glycolysis and preventing futile cycling with gluconeogenesis, where a different enzyme catalyzes the reverse reaction. In the context of cancer cell metabolism, GAPDH represents a particularly critical control point in glycolysis, as many cancer cells exhibit extraordinary dependence on rapid glucose consumption and glycolytic flux despite the availability of mitochondrial oxidative phosphorylation[27][30]. The rate of glycolytic flux through GAPDH is a primary determinant of the overall rate of glucose consumption in these highly metabolic cancer cells, making GAPDH an attractive therapeutic target for cancer therapy[27]. The Km of GAPDH for glyceraldehyde-3-phosphate is remarkably low under physiological conditions, and the enzyme shows positive cooperativity in substrate binding due to its tetrameric organization, meaning that binding of substrate to one subunit enhances binding affinity in the other subunits[1]. This positive cooperativity, combined with the enzyme's sensitivity to various post-translational modifications and protein-protein interactions, allows GAPDH to serve as a dynamic metabolic valve that responds sensitively to cellular conditions.

Catalytic Mechanism: Covalent and General Acid-Base Catalysis

GAPDH employs an elegant and well-characterized catalytic mechanism that involves both covalent catalysis and general acid-base catalysis to accelerate the rate of the oxidative phosphorylation reaction by multiple orders of magnitude[1][2][5]. The reaction proceeds through a highly ordered sequence of steps involving specific amino acid residues in the active site that have been identified and characterized through extensive structural, biochemical, and computational analyses[2][5][42]. The catalytic cysteine residue, located at position 149 in the lobster enzyme (position 152 in human GAPDH), serves as the critical catalytic nucleophile that initiates the reaction[5][42]. In the initial oxidation step, this cysteine residue attacks the carbonyl carbon of glyceraldehyde-3-phosphate, forming a thiohemiacetal intermediate with the substrate[1][2][5]. A nearby histidine residue (position 175 in lobster, position 176-177 in human GAPDH) acts as a general base, deprotonating the cysteine thiol group to enhance its nucleophilic character and facilitating the carbonyl addition reaction[5][42]. The resulting thiohemiacetal intermediate is then oxidized through a hydride transfer to the nicotinamide ring of the NAD+ cofactor, which serves as the electron acceptor in the oxidation reaction[2][5][42]. This hydride transfer is facilitated by the same histidine residue acting as a general acid, which protonates the developing oxygen anion and stabilizes the transition state[5][42]. The oxidation of the thiohemiacetal intermediate yields a thioacyl-enzyme intermediate, in which the substrate remains covalently attached to the cysteine residue through a thioester bond[1][2][5].

Following the formation of the thioacyl-enzyme intermediate, the inorganic phosphate substrate attacks the thioacyl carbon, forming a second tetrahedral intermediate[1][2][5]. The phosphate group, activated by the nearby arginine and other active site residues, attacks the carbon of the thioester bond, leading to the formation of a mixed anhydride between the phosphate and the substrate carbon[1][2][5]. This tetrahedral intermediate is then resolved through protonation of the cysteine thiolate by the histidine residue acting as a general acid, releasing the product 1,3-bisphosphoglycerate while regenerating the free cysteine thiol group with proper protonation state[1][2][5][42]. The remarkable feature of this mechanism is that the same cysteine-histidine catalytic pair accomplishes both the initial substrate activation through deprotonation and the subsequent product formation through acid catalysis, representing an economical utilization of catalytic machinery[5][42]. The NADH product is released rapidly from the enzyme following hydride transfer, and NAD+ is subsequently regenerated and becomes available for the next catalytic cycle[1][2]. Molecular dynamics simulations employing quantum mechanical/molecular mechanical (QM/MM) approaches have elucidated the individual roles of the inorganic phosphate and the substrate phosphate group, demonstrating that the oxidoreduction reaction occurs preferentially at the inorganic phosphate binding site, with arginine residues providing critical substrate binding stabilization[2].

Non-Metabolic Functions and Moonlighting Activities

Beyond its well-established role in glycolysis, GAPDH has emerged as a remarkable example of protein moonlighting, engaging in diverse cellular processes that appear wholly unrelated to its classical enzymatic function[1][8][19][26][31][36][39]. These non-metabolic functions include transcriptional regulation, initiation of apoptotic cell death, endoplasmic reticulum-to-Golgi vesicle transport, heme homeostasis and trafficking, DNA damage sensing and repair, telomere maintenance, calcium signaling modulation, cytoskeletal dynamics, and antimicrobial defense[1][7][8][19][20][25][36][39][43][46]. The ability of GAPDH to engage in such disparate functions is not a consequence of promiscuous interactions but rather reflects sophisticated regulatory mechanisms involving post-translational modifications, protein-protein interactions, subcellular localization, and oligomerization state changes that direct GAPDH to specific cellular compartments and protein complexes.

Nuclear Translocation and Apoptosis Regulation

One of the most extensively studied non-metabolic functions of GAPDH is its role in promoting programmed cell death through a complex signaling cascade initiated by nitric oxide (NO) and mediated by S-nitrosylation of the catalytic cysteine residue[1][7][8][20][26][36]. Under conditions of cellular stress, including exposure to nitric oxide donors, oxidative stress, or apoptotic stimuli, GAPDH undergoes S-nitrosylation at its active site cysteine (position 152 in human GAPDH), which covalently modifies the protein through the attachment of a nitrogen monoxide group to the sulfhydryl group[1][7][8][20][26]. This S-nitrosylation of GAPDH represents a reversible post-translational modification that serves as a cellular signal triggering translocation of GAPDH from the cytoplasm to the nucleus[1][7][8][20][36]. The S-nitrosylated GAPDH interacts with and binds to Siah1, a RING-type E3 ubiquitin ligase, and this interaction is significantly enhanced by the S-nitrosylation modification[1][8][20][26]. The Siah1 protein contains a nuclear localization signal that mediates the translocation of the GAPDH-Siah1 complex into the nucleus[1][20][36]. Once in the nucleus, GAPDH stabilizes Siah1, which then targets nuclear proteins for polyubiquitination and proteasomal degradation, leading to the activation of apoptotic pathways and ultimately cell death[1][7][20]. The specificity of the Siah1-mediated protein degradation is modulated by GAPDH's interaction with target proteins, effectively coupling GAPDH localization to the selective degradation of pro-survival nuclear proteins[1][20][36].

In parallel with the Siah1-mediated pathway, nuclear GAPDH engages in direct interaction with the transcriptional regulator and tumor suppressor p53, which serves as a master coordinator of apoptotic gene expression[7][35][56]. GAPDH has been shown to form direct complexes with p53 and to facilitate p53 binding to the histone acetyltransferase p300 and its closely related homolog CBP[7][35]. The nitrosylated GAPDH is acetylated by the p300/CBP complex at lysine 160, a modification that appears to be critical for GAPDH's pro-apoptotic activity[7][35][36]. The p300/CBP complex is autoacetylated in response to the GAPDH-mediated stimulus, thereby increasing its acetyltransferase activity toward p53 and other transcriptional targets[7]. This leads to the acetylation of p53 and enhanced binding of p53 to the promoter regions of pro-apoptotic genes including PUMA, BAX, and p21[7][35]. The recruitment of GAPDH, p53, and p300 to these apoptotic gene promoters has been demonstrated through chromatin immunoprecipitation experiments, providing direct evidence for GAPDH's role in coordinating the transcriptional activation of apoptotic programs[7][35]. The deprenyl compound, which has clinical utility in Parkinson's disease treatment, has been shown to prevent S-nitrosylation of GAPDH and thereby reduce its apoptotic function, suggesting potential therapeutic strategies for modulating GAPDH-mediated apoptosis[1].

Metabolic Switching and the GAPDH Redox Switch

In response to oxidative stress, GAPDH functions as a reversible metabolic switch that redirects cellular carbohydrate flux away from glycolysis toward the pentose phosphate pathway, thereby enabling the generation of the critical reducing cofactor nicotinamide adenine dinucleotide phosphate (NADPH)[1][14][17]. When cells experience oxidative stress through exposure to hydrogen peroxide, superoxide, or other reactive oxygen species, the catalytic cysteine residue of GAPDH undergoes rapid oxidation to form cysteine sulfenic acid (Cys-SOH), which represents a reversible but catalytically incompetent form of the enzyme[1][14][17][36][42]. This oxidative inactivation of GAPDH represents a controlled cellular response rather than random protein damage, and it is mediated through the redox sensitivity of the active site cysteine residue[1][14][17][36][38]. The inactivation of GAPDH causes a temporal rerouting of metabolic flux from glycolysis to the pentose phosphate pathway, allowing the cell to generate increased amounts of NADPH through the activities of glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase[1][14][36][38]. This metabolic redirection is physiologically critical because NADPH serves as the reducing substrate for major cellular antioxidant and redox regulatory enzymes including the glutathione/glutaredoxin system and the thioredoxin system, which together constitute the primary mechanisms for controlling cellular redox homeostasis and protecting cells from oxidative damage[1][14][36][38].

Recent studies have demonstrated that the GAPDH redox switch also plays a critical role in the physiology of tumor cells under stress conditions[17]. Cells expressing a GAPDH mutant lacking the catalytic cysteine residue and thereby unable to undergo oxidative inactivation retain normal glycolytic activity but fail to activate the pentose phosphate pathway or enhance their reductive capacity in response to oxidative stress[17]. These findings demonstrate that the GAPDH redox switch represents an essential mechanism for cell survival under oxidative stress conditions and is required for the anchorage-independent growth characteristic of transformed cells and for tumor formation in vivo[17]. The induction of additional oxidative stress through chemotherapy or radiotherapy synergizes with the deactivation of the GAPDH redox switch to suppress tumor growth, suggesting that combinations of chemotherapy with inhibitors of GAPDH redox switching may represent an effective therapeutic strategy[17]. The oxidative inactivation of GAPDH can be reversed through the action of glutaredoxins and thioredoxins, which catalyze the reduction of the sulfenic acid form back to the native thiol form, allowing GAPDH to regain its catalytic activity once the oxidative stress has been resolved[36][42].

Heme Metabolism and Chaperone Functions

A surprising discovery in the study of GAPDH's non-metabolic functions is that GAPDH functions as a heme chaperone protein that binds and allocates labile heme to specific cellular protein targets[15][18][52]. This function was discovered through the observation that GAPDH exhibits robust heme-binding capacity both in vitro and in mammalian cells, and that substitution of a conserved histidine residue critical for heme binding antagonizes the delivery of heme to downstream hemeprotein targets despite dramatically increasing cellular concentrations of labile heme[15]. This apparent paradox led to the realization that GAPDH serves as an essential repository and allocator of bioavailable heme within cells, holding labile heme in a form that is protected from generating reactive oxygen species while remaining available for transfer to specific protein targets[15]. The heme-binding property of GAPDH has been shown to be functionally important for heme insertion into specific proteins including the inducible nitric oxide synthase (iNOS) and the transcription factor Hap1[15][52]. Notably, the heme-binding capacity of GAPDH can be regulated through S-nitrosylation of the catalytic cysteine residue, which decreases GAPDH's heme-binding affinity and potentially redirects heme metabolism toward other cellular pathways[52]. The role of GAPDH in heme trafficking appears to be evolutionarily conserved, with studies in the malaria parasite Plasmodium falciparum revealing that GAPDH mutations affecting heme binding and glycolytic activity influence antimalarial drug sensitivity and parasite metabolism[33]. The connection between GAPDH's glycolytic function and its heme chaperone function is particularly evident in the parasite, where heme binding inhibits glycolytic activity, effectively coupling metabolic state to heme availability.

RNA Binding and Post-Transcriptional Gene Regulation

GAPDH has emerged as a non-canonical but significant RNA-binding protein that regulates cellular mRNA stability, translation, and subcellular localization[19][31][49]. GAPDH binds to various RNA scaffolds including transfer RNAs (tRNAs), cellular mRNAs with AU-rich elements in their three-prime untranslated regions (3′-UTRs), and viral RNAs[19][31]. The RNA binding capacity of GAPDH is mediated through residues located within the NAD+ binding domain, and the interaction between GAPDH and RNA can be competed by NAD+ in a concentration-dependent manner, suggesting that the NAD+ binding site and the RNA binding site may partially overlap or adopt similar conformations[19][31]. GAPDH has been shown to bind the core AU-rich element from the tumor necrosis factor-alpha (TNF-α) 3′ UTR mRNA through a sequential two-step mechanism that yields a high-affinity initial complex followed by a lower-affinity complex with distinct functional properties[19][31]. The binding of GAPDH to TNF-α mRNA promotes mRNA stabilization, which increases TNF-α protein production and is associated with progression or recurrence in various disease states[19]. Similarly, GAPDH binding to the 3′-UTRs of other mRNAs including those encoding colony-stimulating factor-1 (CSF-1) and connective tissue growth factor (CCN2) promotes transcript stabilization and protein expression[19]. Conversely, GAPDH binding to other mRNAs including those encoding cyclooxygenase-2 (Cox-2) and endothelin-1 (ET-1) destabilizes the transcripts and reduces protein expression, suggesting that GAPDH can function either as an mRNA stabilizer or destabilizer depending on the specific target sequence and RNA structure[19].

GAPDH has additionally been shown to regulate protein translation through interactions with specific mRNAs, independent of effects on mRNA stability[19]. In activated T cells, GAPDH inhibits the translation of interferon-gamma (IFN-γ) and interleukin-2 (IL-2) mRNAs, thereby modulating the effector functions of these immune cells in relation to their glycolytic status[19]. GAPDH also regulates the translation of the AT1A receptor mRNA, which encodes a critical regulator of cardiovascular homeostasis, through binding to regulatory sequences in the 3′-UTR and modulating translation efficiency in response to oxidative stress[19]. The remarkable feature of GAPDH's role in post-transcriptional gene regulation is that its RNA-binding activity can be modulated by post-translational modifications including phosphorylation and oxidation, allowing cellular stress signals to be transduced to the control of gene expression through GAPDH as an intermediary[19][31]. The specificity of GAPDH for different target mRNAs appears to be determined by both the primary sequence context of AU-rich elements and the secondary and tertiary structures of the mRNA targets, with the dimer and tetramer interfaces of GAPDH playing roles in determining RNA binding specificity[19][31][49].

Endoplasmic Reticulum-to-Golgi Vesicular Transport

GAPDH has been implicated in the regulation of vesicular transport between the endoplasmic reticulum (ER) and the Golgi apparatus, which represents a critical pathway for the secretion of proteins and the trafficking of lipids[1][21][24]. GAPDH is recruited to the ER-derived vesicular-tubular clusters through interaction with the small GTPase rab2, where it participates in the formation of COPI-coated vesicles that mediate retrograde transport from the Golgi to the ER[1][21][24]. The GAPDH protein can be activated through tyrosine phosphorylation by the Src family kinase, which enhances its capacity to facilitate COPI vesicle formation and fusion[1][21][24]. Studies examining GAPDH's role in vesicular transport have demonstrated that GAPDH serves as an adaptor or scaffolding protein that facilitates the interaction between transport machinery components, though the precise molecular mechanism by which its glycolytic activity relates to its transport functions remains incompletely understood[1][24]. GAPDH has also been shown to enhance interactions between microtubules and the N-myristoylated calcium-binding protein p22, which facilitates the coupling of microtubule dynamics with membrane trafficking events[1][41]. During starvation conditions, GAPDH undergoes redistribution to membrane compartments through AMPK-dependent phosphorylation at serine 122, where it inhibits protein transport pathways through targeting ADP-ribosylation factor-1 (ARF1) GTPase-activating proteins, thereby suppressing energy-consuming transport reactions while autophagy is activated[44][47].

Telomere Homeostasis and Cell Aging

GAPDH plays a direct and regulatory role in telomere maintenance by binding to the telomerase RNA component (TERC) and inhibiting telomerase activity[43][46]. The GAPDH Rossmann fold, which contains the NAD+ binding site, has been identified as the primary binding interface for telomeric DNA and the telomerase RNA component[43][46]. GAPDH binding to telomeric DNA and TERC is inhibited by NAD+ in a concentration-dependent manner, with an inhibitory concentration of 13.1 micrometers, suggesting that cellular NAD+ levels and thus metabolic status may regulate GAPDH's telomere-binding function[46]. The inhibition of telomerase activity by GAPDH is reversible and subject to regulation by the substrate glyceraldehyde-3-phosphate and the nitric oxide donor S-nitrosoglutathione (GSNO), indicating that metabolic state and redox conditions control this function[46]. The binding of GAPDH to the telomerase complex results in shortened telomere length and impaired telomere maintenance in cells expressing high levels of exogenous GAPDH, leading to cellular senescence and the arrest of cancer cell proliferation[46]. This function of GAPDH appears to link metabolic activity to cellular aging, as the most metabolically active cells with highest glycolytic flux might be expected to have the greatest GAPDH-mediated telomerase inhibition, potentially accelerating the metabolic or replicative senescence of rapidly dividing cells. The molecular interaction between GAPDH and the telomerase complex is mediated through a specific lysine residue in the GAPDH catalytic domain, as mutation of this residue (K259N in human GAPDH) abolishes telomere shortening and telomerase inhibition while maintaining other GAPDH functions[46].

DNA Damage Sensing and Repair Functions

GAPDH has been increasingly recognized as a participant in DNA damage response and repair mechanisms, participating in both base excision repair (BER) and homologous recombination (HR) repair pathways[1][25][35][56]. In response to DNA double-strand breaks (DSBs), GAPDH translocates to the nucleus where it directly interacts with histone deacetylase-1 (HDAC1) and facilitates the deacetylation of the recombinase RAD51[25]. The activation of HDAC1 by GAPDH occurs through the displacement of HDAC1 from its repressor protein Maspin, thereby increasing HDAC1 catalytic activity[25]. The HDAC1-mediated deacetylation of RAD51 increases the stability of the RAD51 protein and enhances its capacity to promote homologous recombination repair, thereby facilitating the error-free repair of DNA double-strand breaks[25]. GAPDH has also been shown to participate in base excision repair through its capacity to bind DNA directly, recognize abasic sites, and stimulate the activity of the endonuclease APE1, which catalyzes the critical incision step in BER[25][35]. The apparent lack of a classical nuclear localization signal in GAPDH has prompted investigation of the mechanism of GAPDH nuclear import in response to DNA damage, with evidence suggesting that GAPDH nuclear localization may involve carrier proteins or non-canonical import mechanisms[25]. The involvement of GAPDH in DNA repair processes represents an important coupling of metabolic activity to genome maintenance, as cells with high glycolytic activity and thus elevated GAPDH levels may be expected to have enhanced capacity for DNA repair, facilitating survival after DNA damage[25][35].

Post-Translational Modifications and Regulation

The functional diversity of GAPDH is in large part dependent upon its susceptibility to multiple forms of post-translational modification, which regulate its enzymatic activity, subcellular localization, protein-protein interactions, and moonlighting functions[1][8][26][35][39][42]. These modifications include S-nitrosylation, phosphorylation, acetylation, glutathionylation, S-thiolation, oxidation, and other covalent modifications, many of which are reversible and serve as cellular signaling mechanisms responsive to metabolic status and cellular stress[1][8][26][35][39][42].

S-Nitrosylation and Oxidative Modifications

S-nitrosylation represents one of the most intensively studied post-translational modifications of GAPDH, involving the covalent attachment of a nitrogen monoxide group to cysteine residues to form S-nitrosothiols[1][8][11][26][35]. The catalytic cysteine residue at position 152 in human GAPDH is particularly susceptible to S-nitrosylation, and this modification has multiple consequences depending on the specific context and cell type[1][8][11][26]. S-nitrosylation of GAPDH at the catalytic cysteine is reversible and causes enzyme inactivation while simultaneously triggering the binding to and stabilization of Siah1, the E3 ubiquitin ligase that mediates nuclear protein degradation[1][8][11][20][26][35]. The S-nitrosylation of GAPDH also decreases its affinity for the band 3 protein of erythrocyte membranes and other binding partners, potentially allowing GAPDH to dissociate from certain protein complexes and associate with apoptotic machinery[1][8][11]. Mass spectrometric analyses have revealed that S-nitrosylation of GAPDH can lead to further oxidation of the catalytic cysteine to form cysteine sulfenic acid (Cys-SOH) and eventually cysteine sulfinic acid (Cys-SO2H) and cysteine sulfonic acid (Cys-SO3H)[8][26][35]. These higher oxidation states represent essentially irreversible modifications that can trigger committed apoptotic signaling cascades[8][26][35]. Importantly, not all S-nitrosylation events at GAPDH are apoptotic; under certain conditions, S-nitrosylation can be protective by modulating GAPDH interaction with other signaling proteins and preventing its aggregation[8][26][35]. The protective cytosolic protein GOSPEL (GAPDH's competitor Of Siah Protein Enhances Life) has been identified as a competitive inhibitor of GAPDH-Siah1 binding that prevents S-nitrosylated GAPDH nuclear translocation and apoptosis[8][26][36].

Oxidative modifications of GAPDH, distinct from S-nitrosylation but often occurring in concert with it, include glutathionylation, where a reduced glutathione molecule becomes covalently attached to the catalytic cysteine through formation of a mixed disulfide bond[8][36][38][42]. The S-glutathionylation of GAPDH (GAPDH-SSG) serves as a protective mechanism that shields the catalytic cysteine from irreversible over-oxidation during oxidative stress, and the glutathionylated form can be subsequently reduced by glutaredoxins and thioredoxins to regenerate the native cysteine thiol[8][36][38][42]. This reversible modification allows GAPDH to function as a redox switch that toggles between its active glycolytic form and an inactivated form during oxidative stress, thereby redirecting glucose metabolism toward NADPH production through the pentose phosphate pathway[36][38][42]. The plant cytoplasmic GAPDH exhibits similar redox regulation through glutathionylation and S-nitrosylation, suggesting that these regulatory mechanisms are evolutionarily ancient and highly conserved[42]. The oxidation of GAPDH by hydrogen peroxide leads to the formation of the sulfenic acid intermediate, which is relatively unstable and can either be reduced back to the native cysteine thiol or undergo further oxidation to more stable higher oxidation states[42]. The presence of reduced glutathione and the activities of glutaredoxins and thioredoxins influence whether the oxidized GAPDH undergoes reduction and reactivation or further oxidation and commitment to apoptotic pathways[42].

Phosphorylation and Acetylalanylation

Phosphorylation of GAPDH at various serine, threonine, and tyrosine residues has been identified as a critical regulatory modification affecting its subcellular localization, protein-protein interactions, and enzymatic activity[3][22][39][44][47][49]. The phosphorylation of GAPDH at threonine 237 by protein kinase B (PKB/Akt) inhibits both the nuclear translocation of GAPDH and its pro-apoptotic activity in ovarian cancer cells, suggesting a survival function for this modification in certain cell types[35][39]. In contrast, phosphorylation of GAPDH at serine 122 by the metabolic sensor AMP-activated protein kinase (AMPK) promotes nuclear translocation of GAPDH during conditions of glucose starvation and energy stress[44][47]. This phosphorylation is required for GAPDH to translocate to the nucleus and bind to the NAD+-dependent deacetylase Sirtuin 1 (Sirt1), which activates a transcriptional program promoting autophagy and cellular energy conservation[44][47]. The phosphorylation of GAPDH at various tyrosine residues by Src family kinases has been shown to regulate its capacity for heme binding and its role in endoplasmic reticulum-to-Golgi transport[1][21][22]. Recent proteomic and structural studies have identified phosphorylation sites within the NAD+ binding center of GAPDH at positions Y94, S98, and T99, and mutation of these residues significantly reduces the affinity of GAPDH for its NAD+ cofactor, demonstrating that post-translational modifications within the active site can profoundly impact catalytic function[3]. Acetylation of GAPDH at lysine residues K117, K227, and K251 has been shown to promote nuclear translocation and enhance GAPDH's pro-apoptotic activity[35][39]. These acetylation modifications are catalyzed by the histone acetyltransferase p300/CBP complex and may represent a mechanism through which acetyltransferase activity toward GAPDH is coupled to transcriptional activation of pro-apoptotic genes[35][39].

O-linked N-acetylglucosaminylation

O-linked N-acetylglucosamine modification (O-GlcNAcylation) of GAPDH, primarily at threonine 227, has been shown to disrupt the normal tetrameric oligomerization of GAPDH and promote its nuclear translocation[36][39]. This modification is of particular interest because it can alter the proportion of monomeric nuclear GAPDH relative to tetrameric cytoplasmic GAPDH, thereby modulating the capacity of GAPDH to engage in distinct cellular functions. The O-GlcNAcylation of GAPDH may represent a link between glucose metabolism and the control of GAPDH's moonlighting functions, as the O-GlcNAc transferase utilizes UDP-N-acetylglucosamine as its substrate, which is produced through the hexosamine pathway and signals glucose abundance[36][39]. Monomeric nuclear GAPDH has been shown to associate with the transcription factor Oct-1 and regulate histone H2B expression through a DNA binding complex termed OCA-S, suggesting that the oligomerization state of GAPDH is critical for determining its transcriptional regulatory function[36][39].

Subcellular Localization and Compartmentalization

GAPDH exhibits a dynamic and context-dependent subcellular localization that is critical to its functional specificity[1][9][12][35][36]. Under normal physiological conditions, GAPDH is primarily localized to the cytoplasm, where it participates in glycolysis and other cytoplasmic metabolic processes[1][12][36]. The protein is also substantially present at the plasma membrane and in vesicular compartments, consistent with its roles in membrane trafficking and signaling[12][36]. However, under conditions of cellular stress or in response to specific signaling cascades, GAPDH translocates to the nucleus, where it engages in transcriptional regulation, DNA repair, and apoptosis[1][9][35][36][56]. The nuclear pool of GAPDH is detectable in normal healthy cells but represents a minority fraction of total GAPDH; however, the absolute nuclear concentration of GAPDH appears to be substantial despite this lower relative abundance, reflecting the smaller volume of the nucleus compared to the cytoplasm[9].

Quantitative mass spectrometry studies in oocytes have estimated that the nuclear concentration of GAPDH is approximately one thousand-fold lower than the cytoplasmic concentration when expressed as molar quantities in the isolated nucleoplasm compared to associated cytoplasm, yet the absolute amount of GAPDH in the nucleus per unit nuclear volume may be considerable[9]. The nuclear localization of GAPDH does not appear to represent stress-induced aggregation during the isolation procedure, as GAPDH nuclear localization is observed in both freshly dissected nuclei from intact ovary tissue and nuclei from isolated oocytes maintained overnight in culture, indicating that nuclear GAPDH is a feature of normal cell physiology in oocytes[9]. Furthermore, biochemical analysis of the oligomerization state of nuclear and cytoplasmic GAPDH has demonstrated that both pools exist predominantly as tetrameric complexes, indicating that the nuclear GAPDH maintains its active quaternary structure[9]. The finding that the cytoplasmic and nuclear pools of GAPDH exhibit the same isoform expression pattern suggests that isoform switching does not underlie differences in activity behavior between compartments[9]. This observation is particularly interesting because it implies that the differences in GAPDH function between the nucleus and cytoplasm arise from the distinct biochemical environments of these compartments, the specific protein-protein interactions available in each location, and potentially the different substrates available in each cellular compartment[9].

The mechanism of GAPDH nuclear translocation in response to apoptotic stimuli is not yet fully understood, as GAPDH lacks a classical nuclear localization signal and must therefore be transported by alternate mechanisms[25][35]. The S-nitrosylated form of GAPDH binds to Siah1, an E3 ubiquitin ligase that possesses a nuclear localization signal, and this interaction is thought to facilitate nuclear import of the GAPDH-Siah1 complex[1][20][35][36]. Additionally, post-translational modifications including acetylation and phosphorylation may expose hidden localization signals or facilitate binding to carrier proteins that mediate nuclear import[25][35][39]. Once in the nucleus, GAPDH appears to be retained through interactions with specific nuclear proteins and DNA, and the classical nuclear export signal present in GAPDH becomes exposed when the protein unfolds or dissociates from the tetrameric structure, potentially allowing nuclear export of the protein following the completion of its nuclear functions[8][26][35][36].

GAPDH also localizes to mitochondria under certain conditions, where exogenously expressed GAPDH has been shown to associate with the voltage-dependent anion channel 1 (VDAC1) and promote mitochondrial membrane permeabilization and the release of pro-apoptotic proteins[36][38]. The biological significance of mitochondrial GAPDH and whether the endogenous GAPDH pool translocates to mitochondria or whether this represents an artifact of overexpression requires further investigation[36][38]. GAPDH's involvement in endoplasmic reticulum-to-Golgi transport places it at critical junction sites between cellular compartments, and its interaction with microtubules and actin cytoskeleton suggests a role in coupling metabolic activity to cytoskeletal organization and dynamics[1][24][36][38][41].

Regulation by Calcium Signaling and Metabolic State

The activity of GAPDH and its non-metabolic functions are subject to regulation by intracellular calcium signaling through direct interaction with the inositol 1,4,5-trisphosphate receptor (IP3R), which is one of the principal calcium release channels in eukaryotic cells[37][40]. GAPDH binds selectively to the IP3R through protein-protein interactions, and the proximity of GAPDH to the IP3R channel allows the local generation of NADH through GAPDH's enzymatic activity, which in turn regulates intracellular calcium signaling through modulation of the redox environment surrounding the IP3R[37][40]. This coupling of GAPDH glycolytic activity to calcium signaling represents an elegant mechanism through which cellular energy metabolism can directly influence intracellular calcium homeostasis, a process essential for numerous cellular functions including muscle contraction, synaptic transmission, and gene transcription[37][40]. The cardiac ATP-sensitive potassium (KATP) channel represents another example of GAPDH's role in integrating metabolic status with cellular signaling, as GAPDH and the aldolase A enzyme have been identified as components of a protein complex associated with the KATP channel, positioning glycolytic enzymes to directly sense and respond to changes in cellular ATP and ADP levels[55][58].

Disease Pathophysiology and Clinical Significance

Cancer and GAPDH Upregulation

GAPDH is markedly overexpressed in multiple human cancer types, including melanoma, non-small cell lung cancer, hepatocellular carcinoma, and gastric cancer, and its expression level correlates positively with tumor progression, malignancy, and poor patient prognosis[1][27][30][35]. The selective upregulation of GAPDH in cancer cells appears to be driven by the metabolic dependence of cancer on rapid glucose consumption and glycolytic flux, as cancer cells exhibit enhanced glucose uptake and glycolytic capacity despite the availability of mitochondrial oxidative phosphorylation[27][30][35]. The association between GAPDH upregulation and cell cycle progression is particularly evident in non-small cell lung cancer, where GAPDH expression correlates with expression of genes involved in cell cycle regulation, and this association has been formalized into the concept of GAPC genes (GAPDH Associated Cell Cycle genes) whose upregulation is correlated with cancer aggressiveness[30]. The multifunctional nature of GAPDH means that its upregulation in cancer cells provides advantages beyond enhanced glycolytic capacity, including anti-apoptotic functions that protect cancer cells from death signals and enhanced telomerase activity regulation that permits unlimited replicative potential[1][30][35]. Indeed, GAPDH has been shown to protect against telomere shortening induced by chemotherapeutic drugs that stimulate the production of ceramide, suggesting a role in cancer cell survival during therapy[1]. The depletion of GAPDH through targeted knockdown or the selective inhibition of GAPDH has been shown to induce senescence in tumor cells, presenting a novel therapeutic strategy for the selective control of cancer cell growth[1][27]. The specific inhibition of GAPDH through the natural compound koningic acid has demonstrated selective anti-cancer activity and has been proposed as a starting point for the development of novel anti-GAPDH therapeutics[27].

Neurodegenerative Diseases and Nuclear GAPDH Accumulation

Increased nuclear GAPDH accumulation has been consistently observed in vulnerable neurons in postmortem brain samples from patients with multiple neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, Huntington's disease, Machado-Joseph disease, dentatorubral-pallidoluysian atrophy (DRPLA), and glaucoma[56]. The accumulation of nuclear GAPDH in the substantia nigra neurons affected in Parkinson's disease and in the retinal ganglion cells affected in glaucoma suggests that GAPDH-mediated apoptosis may contribute to the selective neuronal vulnerability characteristic of these disorders[56]. Furthermore, the fraction of cerebrospinal fluid obtained from patients with Parkinson's disease induces apoptosis when added to cultured cells, and immunological analysis suggests that GAPDH is a component of this pro-apoptotic activity[56]. The antibodies raised against nuclear GAPDH in apoptotic cells have been found to react with amyloid plaques from Alzheimer's disease postmortem samples, and GAPDH has been shown to bind to C-terminal fragments of the amyloid precursor protein, suggesting a potential mechanistic link between GAPDH and the pathogenic processes in Alzheimer's disease[56]. The presence of high molecular weight GAPDH immunoreactive species in Alzheimer's disease samples, presumably representing GAPDH aggregates or GAPDH bound to other proteins, has been proposed to contribute to the pathogenic aggregation processes characteristic of Alzheimer's disease[56].

The potential therapeutic targeting of GAPDH to prevent its nuclear accumulation and pro-apoptotic activity represents a novel approach to neuroprotection in neurodegenerative diseases. Several small-molecule compounds have been identified that exhibit anti-apoptotic activity through interaction with GAPDH and prevention of its nuclear accumulation[56]. The compound CGP 3466, which has been shown to prevent GAPDH nuclear accumulation and promote neuroprotection in cellular models, has advanced to Phase II clinical trials as a disease-modifying agent for Parkinson's disease[56]. Other compounds including donepezil and THA, which are marketed as symptomatic therapies for Alzheimer's disease, appear to function at least in part through interaction with GAPDH and modulation of its nuclear accumulation and pro-apoptotic activity[56]. The mechanism by which these compounds interact with GAPDH and prevent nuclear accumulation is not fully characterized, though they appear to interact with specific regulatory regions distinct from the active site[56].

Diabetes Mellitus and Vascular Complications

In the pathophysiology of diabetes mellitus, GAPDH plays a critical role in linking hyperglycemia-induced oxidative stress to the activation of multiple pathogenic pathways[57][60]. The inhibition of GAPDH activity by mitochondrial superoxide production in hyperglycemic conditions causes the accumulation of glycolytic intermediates upstream of GAPDH, including glyceraldehyde-3-phosphate, which are diverted into alternative metabolic pathways including the polyol pathway, protein kinase C pathway, and the hexosamine pathway[57][60]. These pathways are implicated in the development of diabetic microvascular complications including diabetic retinopathy, nephropathy, and neuropathy[57][60]. The polyol pathway diverts glucose to sorbitol production, which consumes NADPH and depletes reduced glutathione, compromising cellular antioxidant capacity and exacerbating oxidative stress[57]. The activation of protein kinase C through diacylglycerol generated from glycolytic intermediates promotes vascular inflammatory signaling and endothelial dysfunction[57][60]. The hexosamine pathway produces UDP-N-acetylglucosamine, which leads to excessive O-linked glycosylation of cellular and nuclear proteins, altering their functions and contributing to endothelial dysfunction[57]. The inhibition of GAPDH has been shown to play a significant role in the development and progression of diabetic retinopathy even after reversal of hyperglycemia, suggesting that the GAPDH-mediated pathways become established and self-perpetuating once initiated[60]. Therapies aimed at preventing GAPDH inhibition during hyperglycemia may therefore be effective in preventing the development of diabetic vascular complications[60].

Infectious Diseases and Viral Resistance

Recent studies have revealed an unexpected role for GAPDH in innate immune defense against viral infections, particularly against coronavirus infections including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[51][54]. GAPDH has been shown to bind directly to the spike protein (S protein) of SARS-CoV-2 with nanomolar affinity, and this binding interferes with the interaction between the spike protein and the angiotensin-converting enzyme 2 (ACE2) cellular receptor[51]. The addition of exogenous GAPDH to cell culture medium significantly inhibits the entry of pseudoviral particles decorated with spike protein from multiple SARS-CoV-2 variants including Wuhan, Delta, Kappa, and Omicron variants into susceptible cells[51]. Furthermore, pre-treatment of cells with GAPDH provides significant protection from viral infection that persists for extended periods, suggesting that GAPDH binds to cellular surfaces or remains associated with cells in a manner that inhibits viral entry[51]. This antiviral function of GAPDH appears to be evolutionarily conserved, as GAPDH from multiple sources including rabbit muscle, human, and bacterial sources all exhibit the capacity to inhibit SARS-CoV-2 infection, with human recombinant GAPDH demonstrating the highest potency[51]. The biological significance of this finding is underscored by the fact that GAPDH is known to be secreted from cells, particularly under conditions of cellular stress such as iron depletion or hypoxic stress, suggesting that GAPDH may function as a component of the innate immune response to viral infections[51]. The independent discovery of GAPDH interactions with positive- and negative-strand RNA viruses including bamboo mosaic virus, Japanese encephalitis virus, and tomato bushy stunt virus further supports an evolutionarily conserved antiviral function for GAPDH[51]. The potential development of GAPDH-based therapeutics or enhancement of endogenous GAPDH function could represent a novel approach to preventing or treating coronavirus infections[51].

Therapeutic Potential and Drug Development

The multifunctional nature of GAPDH and its involvement in multiple disease pathways have made it an attractive target for therapeutic intervention. For cancer therapy, the selective inhibition of GAPDH represents an appealing strategy because cancer cells exhibit particular dependence on GAPDH for both their elevated glycolytic flux and the pro-survival functions of nuclear GAPDH[27][35]. The challenge in developing GAPDH inhibitors is achieving selectivity for cancer cells while minimizing toxicity to normal cells that also express GAPDH[27]. One approach to achieving selectivity involves targeting specific non-metabolic functions of GAPDH such as its pro-apoptotic function or its role in telomere maintenance, which may be more dispensable for normal cell survival than glycolytic activity[27][35]. For neurodegenerative disease therapy, the prevention of nuclear GAPDH accumulation and its pro-apoptotic activity through small-molecule compounds represents a neuroprotective strategy that has shown promise in preclinical models and clinical trials[56]. The compounds that have advanced to clinical development, such as CGP 3466, appear to function through preventing GAPDH synthesis and nuclear accumulation rather than through direct inhibition of its enzymatic activity, suggesting that approaches that modulate GAPDH expression or localization may be more therapeutically useful than direct enzymatic inhibitors[56]. For diabetes-related vascular complications, the restoration of GAPDH activity or the prevention of its inhibition through antioxidant strategies represents a potential therapeutic approach[57][60]. The selective activation of the pentose phosphate pathway through GAPDH redox switching inhibition could potentially be exploited for enhancing cellular NADPH production and antioxidant capacity in tissues affected by diabetes[57][60].

The development of GAPDH-based therapeutics must grapple with several fundamental challenges. First, GAPDH is an essential enzyme for glycolysis, and complete inhibition of its activity would be expected to cause cell death through energy depletion, necessitating either partial inhibition, selective targeting of specific GAPDH functions, or targeting of GAPDH in specific tissues or cellular compartments[27][35]. Second, the multiple moonlighting functions of GAPDH mean that inhibitors designed to target one function may unexpectedly affect others, leading to off-target effects[27][35]. Third, the post-translational modification status of GAPDH is likely critical for determining its function, and modulators of these modifications may represent more selective therapeutic approaches than direct enzymatic inhibitors[26][35][39]. Fourth, the expression levels and subcellular localization of GAPDH vary substantially among different cell types and in response to various physiological and pathological states, suggesting that therapeutic efficacy may be context-dependent and require patient stratification based on GAPDH expression and modification status[27][30][35].

Conclusion

GAPDH has evolved from recognition as a simple glycolytic enzyme into a complex and multifunctional protein whose activities encompass metabolism, cell death regulation, DNA repair, heme trafficking, viral defense, and multiple other cellular processes. The ability of GAPDH to engage in such diverse functions arises from its complex structural organization, its susceptibility to multiple post-translational modifications that alter its activity and localization, its capacity to form specific protein-protein interactions in a context-dependent manner, and the distinct biochemical environments of the cellular compartments in which it operates. The catalytic mechanism of GAPDH, involving coupled oxidation and phosphorylation through covalent and general acid-base catalysis, represents an elegant solution to the bioenergetic challenge of coupling an unfavorable phosphorylation reaction to a favorable oxidation reaction. The metabolic switching function of GAPDH, wherein oxidative stress causes the catalytic cysteine to undergo reversible oxidation and inactivation, redirects cellular glucose metabolism from energy production to NADPH generation for antioxidant defense, demonstrating how a single protein can serve as a critical metabolic sensor. The discovery that GAPDH functions as a heme chaperone highlights how evolution can repurpose existing enzymatic machinery to accomplish novel cellular functions that appear unrelated to the original catalytic function.

The involvement of GAPDH in apoptosis and neurodegenerative disease pathophysiology has profound implications for understanding and treating these conditions. The finding that nuclear GAPDH accumulates in vulnerable neurons in neurodegenerative diseases opens the possibility that preventing this nuclear translocation through small-molecule compounds or other interventions could provide neuroprotection. The roles of GAPDH in cancer cell metabolism and survival suggest multiple therapeutic approaches including direct inhibition of glycolytic activity, prevention of nuclear translocation and pro-apoptotic activity, and disruption of its non-metabolic functions including telomerase regulation and heme chaperoning. The unexpected discovery of GAPDH's role in innate immune defense against viral infections suggests that this protein may represent a target for enhancement rather than inhibition in the context of infectious disease, and that understanding how GAPDH inhibits viral entry could reveal new approaches to developing antiviral therapeutics.

Future research on GAPDH must integrate structural, biochemical, and cell biological approaches to fully elucidate the mechanisms through which post-translational modifications control the transition between its various functional states, how its oligomerization state influences its capacity to engage in distinct cellular functions, and how the distinct biochemical environments of different cellular compartments support its diverse activities. The development of compartment-specific inhibitors or modulators that selectively target particular GAPDH functions while preserving others represents a major goal for therapeutic development. Additionally, the investigation of how GAPDH's multiple functions are integrated at the systems level to coordinate metabolism, cell survival or death, DNA repair, and other processes will provide deeper understanding of how a single protein contributes to overall cellular homeostasis and how dysregulation of GAPDH contributes to human disease.

Citations

https://en.wikipedia.org/wiki/Glyceraldehyde_3-phosphate_dehydrogenase
https://pubmed.ncbi.nlm.nih.gov/23389436/
https://pmc.ncbi.nlm.nih.gov/articles/PMC4657119/
https://www.uniprot.org/uniprotkb/P04406/entry
https://www.ebi.ac.uk/thornton-srv/m-csa/entry/911/
https://pubmed.ncbi.nlm.nih.gov/30077773/
https://www.science.org/doi/10.1126/scisignal.127ec247
https://pmc.ncbi.nlm.nih.gov/articles/PMC8615796/
https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0290892
https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2443.2005.00911.x
https://pubmed.ncbi.nlm.nih.gov/8626764/
https://www.proteinatlas.org/ENSG00000111640-GAPDH/subcellular
https://microbiologyinfo.com/glycolysis-10-steps-explained-steps-by-steps-with-diagram/
https://pmc.ncbi.nlm.nih.gov/articles/PMC2246036/
https://pubmed.ncbi.nlm.nih.gov/30012884/
https://www.ncbi.nlm.nih.gov/gene/2597
https://pubmed.ncbi.nlm.nih.gov/37024754/
https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.202101237RR
https://pmc.ncbi.nlm.nih.gov/articles/PMC5120886/
https://pubmed.ncbi.nlm.nih.gov/15951807/
https://rupress.org/jcb/article/138/1/1/15545/Membrane-Dynamics-at-the-Endoplasmic-Reticulum
https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.201902904RR
https://www.proteinatlas.org/ENSG00000196470-SIAH1
https://pubmed.ncbi.nlm.nih.gov/18620527/
https://pmc.ncbi.nlm.nih.gov/articles/PMC10398663/
https://www.tandfonline.com/doi/full/10.1080/14728222.2018.1449834
https://pmc.ncbi.nlm.nih.gov/articles/PMC3635105/
https://pmc.ncbi.nlm.nih.gov/articles/PMC46903/
https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0061262
https://pmc.ncbi.nlm.nih.gov/articles/PMC4268148/
https://www.youtube.com/watch?v=XwBuz00twZQ
https://journals.plos.org/plospathogens/article?id=10.1371%2Fjournal.ppat.1010803
https://www.uniprot.org/uniprotkb/O57479/entry
https://pmc.ncbi.nlm.nih.gov/articles/PMC7285110/
https://pmc.ncbi.nlm.nih.gov/articles/PMC3084531/
https://pubmed.ncbi.nlm.nih.gov/15677321/
https://pubmed.ncbi.nlm.nih.gov/33651246/
https://www.pnas.org/doi/10.1073/pnas.0409657102
https://pmc.ncbi.nlm.nih.gov/articles/PMC1134116/
https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2013.00450/full
https://pubmed.ncbi.nlm.nih.gov/19800890/
https://pmc.ncbi.nlm.nih.gov/articles/PMC6152935/
https://www.ncbi.nlm.nih.gov/gene/26330
https://pmc.ncbi.nlm.nih.gov/articles/PMC3421169/
https://pubmed.ncbi.nlm.nih.gov/26626483/
https://www.uniprot.org/uniprot/K7EP73
https://pmc.ncbi.nlm.nih.gov/articles/PMC4340419/
https://pmc.ncbi.nlm.nih.gov/articles/PMC419859/
https://pmc.ncbi.nlm.nih.gov/articles/PMC10911789/
https://www.pnas.org/doi/10.1073/pnas.1008133107
https://academic.oup.com/nar/article/53/11/gkaf473/8158039
https://www.frontiersin.org/journals/virology/articles/10.3389/fviro.2021.682136/epub
https://pmc.ncbi.nlm.nih.gov/articles/PMC3114533/
https://pmc.ncbi.nlm.nih.gov/articles/PMC518865/
https://pmc.ncbi.nlm.nih.gov/articles/PMC8389282/
https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fj.10-176669
https://neurodegenerationresearch.eu/tag/gapdh/
https://pmc.ncbi.nlm.nih.gov/articles/PMC2606877/

Notes

(GAPDH-notes.md)

GAPDH Gene Review Notes

Colleague Question

Contact: lbl@doe.gov
Key Interest: Classic moonlighting protein example

Key Findings

Canonical Function

Glycolytic enzyme: Glyceraldehyde-3-phosphate dehydrogenase
Catalyzes phosphorylation of G3P to 1,3-BPG (step 6 of glycolysis)
Essential for ATP production in cytoplasm
One of the most abundant cellular proteins

Moonlighting Functions Confirmed

Nuclear roles:
Transcriptional coactivator (OCA-S complex)
DNA repair via APE1 interaction
Telomere maintenance
NAD+-dependent histone deacetylation
Cell death regulation:
S-nitrosylation triggers nuclear translocation
Promotes apoptosis under oxidative stress
Siah1 binding mediates nuclear import
RNA binding:
AU-rich element binding in 3' UTRs
Regulates mRNA stability
Involved in translational control
Membrane functions:
Membrane fusion and trafficking
Iron uptake via transferrin receptor interaction
Phosphatidylserine binding

Why GAPDH is THE Moonlighting Exemplar

Structural basis: Single domain protein with multiple interfaces
Regulation: Post-translational modifications control function switching
Evolution: Ancient enzyme coopted for diverse cellular processes
Clinical relevance: Dysregulation in neurodegeneration, cancer

GO Annotation Review

Accepted 37 core glycolytic annotations
Marked 61 moonlighting functions as non-core but valid
Total of 98 annotations reviewed systematically
Demonstrates GO's challenge with multifunctional proteins

Key Publications

PMID:12829261 - Nuclear functions review
PMID:15752980 - S-nitrosylation and cell death
PMID:21630459 - Comprehensive moonlighting review
PMID:28988822 - Structural basis of multifunctionality

Remaining Questions

How do cells regulate GAPDH function switching?
Can moonlighting functions be selectively targeted therapeutically?
What determines subcellular localization under different conditions?
Are there undiscovered moonlighting functions?

Clinical Significance

Neurodegenerative diseases (Alzheimer's, Parkinson's)
Cancer metabolism and progression
Potential drug target for selective inhibition
Biomarker for oxidative stress

Bioreason Rl Review

(GAPDH-bioreason-rl-review.md)

BioReason-Pro RL Review: GAPDH (human)

Source: GAPDH-deep-research-bioreason-rl.md

Correctness: 4/5
Completeness: 3/5

Functional Summary Review

The BioReason functional summary states:

A soluble cytoplasmic oxidoreductase that uses a nicotinamide-binding module to couple NAD-dependent redox chemistry to aldehyde- and phosphate-handling steps within central carbon metabolism. It assembles as a soluble dehydrogenase that channels triose-phosphate intermediates through a catalytic core to support energy and biosynthetic pathways in the cytoplasm, functioning as a NAD-linked hub that integrates carbohydrate breakdown with cellular energy balance.

This accurately captures GAPDH's core enzymatic function: glyceraldehyde-3-phosphate dehydrogenase activity (GO:0004365) in glycolysis (GO:0006096), using NAD+ as a cofactor. The curated review accepts these as core functions. The description of NAD binding, cytoplasmic localization, and role in central carbon metabolism is correct.

However, the summary has notable gaps:

Moonlighting functions omitted: GAPDH is one of the most well-characterized moonlighting proteins. The curated review describes roles in translational regulation (GO:0006417, kept as non-core), apoptosis (GO:0006915, kept as non-core), innate immune response (GO:0045087, kept as non-core), and nuclear functions (GO:0005634, accepted). BioReason captures none of these.
The GO term predictions are strikingly wrong: The predicted MF terms include "peptidase inhibitor activity" (GO:0030414), "endopeptidase inhibitor activity" (GO:0004866), and entirely omit the actual GAPDH enzymatic activity. This suggests the model's GO term predictions are based on a different or corrupted feature set, not aligned with the functional summary.
The curated review identifies NAD binding (GO:0051287) as accepted and removes several over-broad annotations (GO:0016491 oxidoreductase activity, GO:0016620 oxidoreductase activity acting on aldehydes). BioReason's summary describes the correct chemistry but the GO term output does not match.

Comparison with interpro2go:

There are no GO_REF:0000002 annotations specifically flagged in the curated GAPDH review. BioReason's reasoning from the GAPDH InterPro domains (IPR020831, IPR020828, IPR006424) correctly leads to the dehydrogenase function, which mirrors what interpro2go would produce. However, the disconnect between the sensible functional summary and the wildly inaccurate predicted GO terms (peptidase inhibitor activity?) suggests a systematic problem in the term-prediction module that is separate from the reasoning trace.

Notes on thinking trace

The trace demonstrates competent reasoning about the Rossmann fold, NAD-binding domain, and catalytic domain architecture. The hypothesis about homotetrameric assembly is correct. The trace stays appropriately focused on the enzymatic function without over-interpreting.

Falcon Research

(GAPDH-falcon-research.md)

Falcon Research Report: GAPDH (HUMAN)

Generated using FutureHouse Falcon API

Question: You are a molecular biologist and gene annotation expert conducting comprehensive research to support GO annotation curation.

Provide detailed, well-cited information focusing on:
1. Gene function and molecular mechanisms
2. Cellular localization and subcellular components
3. Biological processes involvement
4. Disease associations and phenotypes
5. Protein domains and structural features
6. Expression patterns and regulation
7. Evolutionary conservation
8. Key experimental evidence and literature

Format as a comprehensive research report with citations suitable for Gene Ontology annotation curation.

Research the Homo sapiens gene GAPDH.

=== UNIPROT METADATA ===
UniProt ID: P04406
Entry Name: G3P_HUMAN
Gene Name: GAPDH
Gene Synonyms: GAPD {ECO:0000303|PubMed:6096136}
Protein Name: Glyceraldehyde-3-phosphate dehydrogenase
EC Number: 2.6.99.-
Organism: Homo sapiens (Human)
NCBI Taxonomy ID: 9606
Function: Has both glyceraldehyde-3-phosphate dehydrogenase and nitrosylase activities, thereby playing a role in glycolysis and nuclear functions, respectively (PubMed:11724794, PubMed:3170585). Glyceraldehyde-3-phosphate dehydrogenase is a key enzyme in glycolysis that catalyzes the first step of the pathway by converting D- glyceraldehyde 3-phosphate (G3P) into 3-phospho-D-glyceroyl phosphate (PubMed:11724794, PubMed:3170585). Modulates the organization and assembly of the cytoskeleton (By similarity). Facilitates the CHP1- dependent microtubule and membrane associations through its ability to stimulate the binding of CHP1 to microtubules (By similarity). Component of the GAIT (gamma interferon-activated inhibitor of translation) complex which mediates interferon-gamma-induced transcript-selective translation inhibition in inflammation processes (PubMed:23071094). Upon interferon-gamma treatment assembles into the GAIT complex which binds to stem loop-containing GAIT elements in the 3'-UTR of diverse inflammatory mRNAs (such as ceruplasmin) and suppresses their translation (PubMed:23071094). Also plays a role in innate immunity by promoting TNF-induced NF-kappa-B activation and type I interferon production, via interaction with TRAF2 and TRAF3, respectively (PubMed:23332158, PubMed:27387501). Participates in nuclear events including transcription, RNA transport, DNA replication and apoptosis (By similarity). Nuclear functions are probably due to the nitrosylase activity that mediates cysteine S-nitrosylation of nuclear target proteins such as SIRT1, HDAC2 and PRKDC (By similarity).
Subcellular Location: Cytoplasm, cytosol
Subunit: Homotetramer (PubMed:16239728, PubMed:16510976). Interacts with TPPP; the interaction is direct (By similarity). Interacts (when S-nitrosylated) with SIAH1; leading to nuclear translocation (By similarity). Interacts with RILPL1/GOSPEL, leading to prevent the interaction between GAPDH and SIAH1 and prevent nuclear translocation (By similarity). Interacts with CHP1; the interaction increases the binding of CHP1 with microtubules (By similarity). Associates with microtubules (By similarity). Interacts with EIF1AD, USP25, PRKCI and WARS1 (PubMed:11724794, PubMed:15628863, PubMed:16501887, PubMed:20644585). Interacts with phosphorylated RPL13A; inhibited by oxidatively-modified low-densitity lipoprotein (LDL(ox)) (PubMed:22771119). Component of the GAIT complex (PubMed:15479637). Interacts with FKBP6; leading to inhibit GAPDH catalytic activity (PubMed:19001379). Interacts with TRAF2, promoting TRAF2 ubiquitination (PubMed:23332158). Interacts with TRAF3, promoting TRAF3 ubiquitination (PubMed:27387501).
======================

Provide a comprehensive report covering function, localization, processes, domains, disease associations, expression, conservation, and relevant GO terms.

IMPORTANT: Focus specifically on the gene identified by the metadata above, particularly the UniProt ID, locus tag, and protein description if provided.

Sometimes different genes in the same organism have the same name. In this case, the gene being reviewed is the one identified by the metadata above.

Comprehensive Research Report on Homo sapiens GAPDH (UniProt ID: P04406) for Gene Ontology Annotation Curation

Abstract
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is one of the most extensively studied proteins in Homo sapiens. Traditionally regarded as a central glycolytic enzyme responsible for the conversion of glyceraldehyde-3-phosphate (G3P) to 1,3‑bisphosphoglycerate, GAPDH has emerged as a prototypical “moonlighting” protein with diverse non‐metabolic functions. These include roles in nuclear regulation, apoptosis, cytoskeletal dynamics, redox signaling, translational control via the GAIT complex, and even innate immunity. Its multifunctionality is further underscored by its dynamic subcellular localization that spans the cytoplasm, nucleus, mitochondria, plasma membrane, and extracellular vesicles. In addition, GAPDH is implicated in a wide spectrum of human diseases ranging from neurodegenerative disorders and cancer to metabolic and autoimmune conditions, underscoring its clinical relevance. This report details the gene’s function and molecular mechanisms, subcellular localizations, participation in biological processes, disease associations, defined protein domains and structural features, expression and regulatory patterns, evolutionary conservation, and the key experimental evidence supporting these roles—all with a view toward rigorous Gene Ontology annotation curation (dominguez2016redoxproteomicprofiling pages 21-22, hoopes2016acryabinteractome pages 84-86, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2).

Introduction
GAPDH (G3P_HUMAN) is encoded by the GAPDH gene in Homo sapiens and has been classically characterized as a housekeeping gene with a fundamental role in glycolysis. Over the past several decades, however, extensive biochemical, cell biological, and proteomic studies have expanded our understanding of GAPDH beyond its canonical metabolic function. Today, GAPDH is well recognized not only as an enzyme catalyzing a critical step in glycolysis but also as a multifunctional regulator that integrates cellular metabolism with regulation of apoptosis, nuclear events, cytoskeletal dynamics, and immune responses. This dual functionality is made possible by its capacity to undergo various post‑translational modifications and to form dynamic associations with multiple protein partners. Consequently, GAPDH has become a paradigm for moonlighting proteins, and accurate Gene Ontology (GO) annotation for its diverse functions remains essential. In this report, we summarize the current knowledge regarding the molecular mechanisms, subcellular compartmentalization, biological processes, disease associations, structural domains, expression patterns, regulation, evolutionary conservation, and experimental evidence pertinent to GAPDH (dominguez2016redoxproteomicprofiling pages 21-22).
Gene Function and Molecular Mechanisms
2.1 Canonical Glycolytic Role
GAPDH’s most widely appreciated function is its pivotal role in glycolysis. In this pathway, the enzyme catalyzes the oxidative phosphorylation of glyceraldehyde-3-phosphate (G3P) into 1,3‑bisphosphoglycerate while concomitantly reducing NAD⁺ to NADH. This reaction is essential for substrate-level phosphorylation and for maintaining cellular redox balance, making GAPDH indispensable for ATP production and metabolic homeostasis (dominguez2016redoxproteomicprofiling pages 21-22). Its enzymatic function has been explored using detailed biochemical assays which have quantified its high rate of catalysis and confirmed its centrality in glycolytic flux (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2).

2.2 Non-Canonical “Moonlighting” Functions
Beyond energy metabolism, GAPDH exhibits a surprising array of non-glycolytic functions. Under conditions of nitrosative and oxidative stress, GAPDH undergoes post‑translational modifications—most notably S‑nitrosylation on key cysteine residues—which can trigger its interaction with the E3 ubiquitin ligase SIAH1. The resulting GAPDH–SIAH1 complex translocates into the nucleus where it contributes to the regulation of gene transcription and the initiation of p53‐dependent apoptotic pathways by upregulating pro‑apoptotic genes such as BAX, PUMA, and p21 (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, hoopes2016acryabinteractome pages 92-93). In addition, acetylation at lysine residues (for example, K117, K227, and K251) further facilitates its nuclear import and modulates its interactions with nuclear target proteins (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4).
Moreover, GAPDH functions as a component of the GAIT (gamma interferon‑activated inhibitor of translation) complex. In response to interferon‑gamma, GAPDH associates with other GAIT components to bind specific stem–loop elements in the 3′‑untranslated region (3′‑UTR) of target mRNAs (such as ceruloplasmin), thereby repressing their translation as a means of finely tuning inflammatory responses (khan2016proteinfunctiondiversity pages 84-88).
GAPDH has also been reported to act as a nitrosylase, transferring nitric oxide groups to nuclear proteins—such as SIRT1, HDAC2, and PRKDC—which modulates DNA repair and transcriptional regulation (dominguez2016redoxproteomicprofiling pages 21-22, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14). Through these diverse mechanisms—ranging from regulation of redox states to modulation of transcription and translation—GAPDH couples metabolic flux to cellular homeostasis and stress adaptation (hoopes2016acryabinteractome pages 84-86, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14).

2.3 Interactions with the Cytoskeleton and Cellular Signaling
In addition to its metabolic and nuclear roles, GAPDH modulates the organization and dynamics of the cytoskeleton. By interacting with calcineurin homologous protein 1 (CHP1), GAPDH enhances CHP1 binding to microtubules, thereby influencing microtubule assembly and intracellular trafficking (dominguez2016redoxproteomicprofiling pages 21-22). These interactions illustrate how GAPDH can directly affect cytoskeletal organization and cell morphology. Furthermore, GAPDH’s interaction with tumor necrosis factor receptor-associated factors (TRAF2 and TRAF3) promotes their ubiquitination, which in turn activates NF‑κB signaling cascades and type I interferon production—a connection that bridges metabolism with innate immunity (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16).
Finally, GAPDH can modulate apoptosis not only through its nuclear interactions but also by engaging with mitochondrial proteins such as the voltage-dependent anion channel 1 (VDAC1). Through these interactions, GAPDH contributes to mitochondrial outer membrane permeabilization (MOMP), leading to the release of cytochrome c and activation of downstream apoptotic cascades (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4). Collectively, these multifaceted molecular mechanisms position GAPDH as a central integrator of diverse signaling pathways that regulate cell survival, programmed cell death, and immune responses (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6).

Cellular Localization and Subcellular Components
3.1 Predominant Cytoplasmic Localization
Under normal physiological conditions, GAPDH is primarily localized in the cytoplasm where it performs its glycolytic function as a homotetramer. Proteomic analyses and immunocytochemical studies consistently demonstrate that GAPDH is among the most abundant proteins in the cytosol, reflecting its essential role in energy metabolism (dominguez2016redoxproteomicprofiling pages 21-22, harshman2013characterizationofmultiple pages 22-22). This cytoplasmic residency is further supported by its classification under Gene Ontology annotations related to the cytosol and glycolytic process (langston2013identificationoftheb pages 37-39).

3.2 Dynamic Subcellular Distribution
Although the cytoplasm is the primary site of action, GAPDH is remarkably dynamic in its subcellular localization. Various stimuli, particularly those involving oxidative or nitrosative stress, trigger the translocation of GAPDH to the nucleus. For instance, S‑nitrosylation facilitates binding to SIAH1 and subsequent nuclear import, thus allowing GAPDH to participate in gene regulation, DNA repair, and apoptotic signaling (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, hoopes2016acryabinteractome pages 91-92). In addition to the nucleus, GAPDH has been identified in mitochondria where it contributes to the regulation of mitochondrial outer membrane permeability and apoptotic cascades (hoopes2016acryabinteractome pages 84-86).
Emerging evidence also points to GAPDH localization in other compartments such as the plasma membrane and extracellular vesicles, indicating potential roles in intercellular communication and receptor-mediated signaling (dominguez2016redoxproteomicprofiling pages 21-22, khan2016proteinfunctiondiversity pages 84-88, hoopes2016acryabinteractome pages 91-92). Together, these findings underscore the subcellular plasticity of GAPDH, enabling it to perform distinct tasks according to cellular context and stress conditions (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6).

3.3 Subcellular Localization in Pathological States
In disease contexts, alterations in GAPDH localization are of particular importance. For example, in certain cancers, GAPDH expression may shift or be differentially regulated at the subcellular level, thereby contributing to metabolic reprogramming and apoptotic resistance (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, kuo2021biomarkerdiscoveryin pages 8-9). Similarly, in neurodegenerative diseases, mislocalization and aggregation of GAPDH—not only in the cytoplasm but also in the nucleus—have been implicated in neuronal cell death (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, hoopes2016acryabinteractomea pages 91-92). These observations highlight that GAPDH’s compartmental distribution is not static but evolves in response to both physiological and pathological stimuli (chang2018proteomicinvestigatingthe pages 9-9, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 6-8).

Involvement in Biological Processes
4.1 Glycolysis and Energy Metabolism
At its most fundamental level, GAPDH is essential for glycolysis. The enzyme’s catalysis of the oxidation and phosphorylation of G3P is a rate‑determining step in this energy-producing pathway, making it critical for ATP production and for the regulation of cellular redox balance through NADH generation (dominguez2016redoxproteomicprofiling pages 21-22, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2). This metabolic role is not only vital under normal conditions but is also accentuated in rapidly proliferating cells, such as in cancer, where elevated glycolytic flux supports the biosynthetic and energetic demands of growth (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16).

4.2 Apoptosis and Cell Death Regulation
Beyond metabolism, GAPDH is a key mediator of programmed cell death. Under oxidative and nitrosative stress, its S‑nitrosylation triggers nuclear translocation and formation of complexes with SIAH1 that activate p53-dependent apoptotic pathways. This process leads to the upregulation of pro‑apoptotic factors and the execution of apoptosis (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4). Additionally, GAPDH’s interaction with mitochondrial components (e.g., VDAC1) further contributes to the intrinsic apoptotic pathway by facilitating mitochondrial outer membrane permeabilization and cytochrome c release (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13).

4.3 Autophagy and Stress Response
Under conditions of nutrient deprivation and cellular stress, GAPDH participates in autophagy—an essential process for recycling damaged proteins and organelles. Activation of AMP‑activated protein kinase (AMPK) during glucose starvation leads to phosphorylation events on GAPDH that promote its nuclear translocation and the subsequent activation of Sirt1‑dependent autophagy (hoopes2016acryabinteractomea pages 92-93, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16). Such regulatory mechanisms ensure cell survival during metabolic stress and contribute to the overall maintenance of cellular homeostasis (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6).

4.4 Regulation of Inflammatory and Immune Responses
GAPDH is also involved in the regulation of inflammatory responses. As a component of the GAIT complex, GAPDH binds to the 3′‑UTRs of specific mRNAs, such as those encoding ceruloplasmin, in response to interferon‑gamma signaling. This interaction suppresses the translation of these transcripts, thereby modulating inflammatory processes (khan2016proteinfunctiondiversity pages 84-88, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14). Furthermore, its interaction with TRAF2 and TRAF3 facilitates the ubiquitination of these proteins, which in turn regulates NF‑κB activation and type I interferon production—key pathways in innate immunity (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2).

4.5 Cytoskeletal Organization and Intracellular Transport
GAPDH’s non‑metabolic functions extend to the regulation of the cytoskeleton. By binding to CHP1, GAPDH enhances the association of CHP1 with microtubules, which is vital for maintaining cellular architecture and supporting intracellular transport (dominguez2016redoxproteomicprofiling pages 21-22). This function underscores GAPDH’s role as an integrator of metabolism and structural organization within the cell (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, bharadwaj2013roleofthe pages 129-129).

4.6 Transcriptional and Translational Regulation
The nuclear functions of GAPDH are also manifested in its ability to affect gene expression. Through its nitrosylase activity, GAPDH modulates the function of nuclear proteins involved in transcription and DNA repair. In the context of the GAIT complex, GAPDH mediates selective translational suppression of inflammatory mRNAs, revealing a finely tuned mechanism by which the cell controls protein synthesis in response to cytokine signaling (khan2016proteinfunctiondiversity pages 84-88, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14).

Disease Associations and Phenotypes
5.1 Neurodegenerative Diseases
Numerous studies have implicated altered GAPDH function in the pathogenesis of neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. Oxidative stress–induced modifications—including S‑nitrosylation and oxidation of critical cysteine residues—can lead to misfolding and aggregation of GAPDH, thereby contributing to neuronal dysfunction and death (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4). These aggregates have been shown to potentiate toxic interactions with misfolded proteins, exacerbating neurodegenerative processes (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14, hoopes2016acryabinteractome pages 91-92).

5.2 Cancer
Cancer cells often exhibit profound metabolic reprogramming, with enhanced glycolysis even in the presence of oxygen (the Warburg effect). GAPDH is frequently overexpressed in various cancers—including pancreatic, lung, esophageal, and breast carcinomas—supporting the metabolic demands of tumor growth and proliferation (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16). In addition, GAPDH’s involvement in anti-apoptotic signaling and its modulation by hypoxia (via HIF‑1α) contribute to tumor cell survival, making it a potential target for cancer therapy (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, kuo2021biomarkerdiscoveryin pages 8-9).

5.3 Metabolic and Diabetic Complications
In metabolic diseases such as diabetes, hyperglycemic conditions lead to the accumulation of reactive metabolites (e.g., methylglyoxal) that modify GAPDH and hamper its enzymatic function. This inactivation can cause an accumulation of upstream glycolytic intermediates, which in turn contribute to cellular stress, mitochondrial dysfunction, and tissue damage associated with diabetic complications (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2).

5.4 Inflammatory and Autoimmune Disorders
GAPDH’s regulatory role in the GAIT complex and its interactions with immune signaling proteins (such as TRAF2 and TRAF3) underscore its importance in modulating inflammatory responses. Dysregulation of these pathways may lead to chronic inflammation and contribute to the pathogenesis of autoimmune diseases. Moreover, anti‑GAPDH antibodies have been implicated in immune infertility, linking GAPDH dysfunction to reproductive disorders (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6, gandini2017spermglyceraldehyde3phosphate pages 5-5, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13).

5.5 Reproductive Biology
A testis‑specific isoform of GAPDH, known as GAPDHS, is critical for sperm energy metabolism and motility. Deficiencies or oxidative modifications of this isoform have been associated with asthenozoospermia, a condition characterized by reduced sperm motility and subsequent male infertility (gandini2017spermglyceraldehyde3phosphate pages 5-5, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2). These findings highlight the role of GAPDH in specialized cellular contexts beyond general metabolism.

Protein Domains and Structural Features
6.1 Oligomeric Structure and Catalytic Domains
Human GAPDH is composed of four identical subunits that assemble into a functional homotetramer, with each subunit having an approximate molecular mass of 36 kDa (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2). Each monomer contains a Rossmann fold domain that is essential for binding NAD⁺/NADP⁺, which is critical for its dehydrogenase activity during glycolysis (kuo2021biomarkerdiscoveryin pages 8-8, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2). The enzyme’s active site is defined by key conserved residues, notably cysteine 152 (C152) and methionine 46 (M46), which are essential for catalysis and substrate recognition (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4).

6.2 Post‑Translational Modifications and Oligomeric Shifts
GAPDH is subject to a variety of post‑translational modifications (PTMs) that modulate its activity, subcellular localization, and protein–protein interactions. S‑nitrosylation, particularly at C152, can induce a transition from the active tetrameric form to alternative oligomeric states (dimeric or monomeric), which are associated with non–glycolytic functions such as nuclear translocation and apoptotic signaling (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13). In addition, acetylation at lysine residues (e.g., K117, K227, K251) further influences GAPDH’s conformational state and facilitates its nuclear import (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13). Phosphorylation events, mediated by kinases such as AMPK and protein kinase C delta (PKCδ), have also been demonstrated to modulate GAPDH’s function in both metabolic and apoptotic contexts (hoopes2016acryabinteractome pages 84-86, hoopes2016acryabinteractomea pages 92-93).

6.3 Interaction Domains and Binding Interfaces
Structural analyses reveal that GAPDH possesses interfaces that enable interactions with a variety of partner proteins. For example, specific binding regions mediate interactions with the small heat shock protein HspB2, which functions to protect GAPDH from aggregation under stress conditions (hoopes2016acryabinteractomea pages 84-86, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4). Furthermore, regions within GAPDH facilitate its incorporation into the GAIT complex and its interaction with immune regulators such as TRAF2/3, linking its structure directly to its roles in inflammation and immune signaling (khan2016proteinfunctiondiversity pages 84-88, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16).

Expression Patterns and Regulation
7.1 Ubiquitous and High-Level Expression
GAPDH is one of the most abundantly expressed proteins in human cells, with intracellular concentrations reaching approximately 0.4 µM—equivalent to nearly 2 million molecules per cell (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2). This high level of expression underpins its role as a housekeeping gene, serving as a standard control in numerous experimental protocols including Western blotting and quantitative PCR (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, harshman2013characterizationofmultiple pages 22-22).

7.2 Tissue Distribution and Isoform Specificity
While the canonical form of GAPDH is ubiquitously expressed across tissues, specialized isoforms exist. Notably, the testis‑specific isoform GAPDHS is expressed exclusively in spermatogenic cells and is essential for sperm motility and fertility. Differential expression patterns of GAPDH and its isoforms have been linked to both normal physiological functions and disease states (gandini2017spermglyceraldehyde3phosphate pages 5-5, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2).

7.3 Regulation Under Stress and Pathological Conditions
The regulation of GAPDH expression is dynamic and responsive to cellular conditions. For instance, under hypoxic conditions—typical of the tumor microenvironment—transcriptional upregulation of GAPDH is frequently observed, mediated in part by hypoxia‑inducible factor 1 (HIF‑1α) (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16). In response to oxidative stress or glucose deprivation, GAPDH undergoes specific PTMs, such as S‑nitrosylation or phosphorylation by AMPK, which not only modulate its enzymatic activity but also promote its translocation to the nucleus to initiate apoptotic or autophagic responses (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 6-8, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6). Such regulatory mechanisms enable the fine‑tuning of GAPDH’s dual roles in metabolism and cell survival, thereby integrating environmental cues with intracellular signaling pathways (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 8-9).

7.4 Post‑Transcriptional and Translational Regulation
Recent studies have also suggested that GAPDH expression can be regulated at the RNA level. Its mRNA stability and translation efficiency are modulated by both intrinsic sequence elements and extrinsic factors—such as its sequestration in ribonucleoprotein complexes—that respond to cellular stress and inflammatory signals (khan2016proteinfunctiondiversity pages 84-88, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14). This additional layer of regulation further emphasizes the critical importance of GAPDH in maintaining cellular homeostasis.

Evolutionary Conservation
GAPDH is one of the most evolutionarily conserved proteins across eukaryotes, reflecting its central role in an ancient and essential metabolic pathway. Comparative sequence analyses have revealed that the catalytic residues (such as C152 and M46) and NAD‑binding domains are highly conserved from lower organisms to mammals, underscoring strong evolutionary pressures to maintain its function (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2). This deep conservation extends not only to its enzymatic function but also to the structural domains that facilitate its “moonlighting” roles, such as nuclear translocation signals and protein–protein interaction interfaces (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14). The ubiquitous expression and conservation of GAPDH highlight its indispensable role in cellular energy metabolism and signal transduction—traits that have been preserved throughout evolution.
Key Experimental Evidence and Literature
9.1 Biochemical and Enzymatic Assays
The glycolytic activity of GAPDH has been characterized through rigorous enzymatic assays that measure the conversion of G3P to 1,3‑bisphosphoglycerate along with concomitant NADH production. Such biochemical studies have provided quantitative estimates of its catalytic efficiency and have laid the foundation for understanding its central role in energy metabolism (dominguez2016redoxproteomicprofiling pages 21-22, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2).
Moreover, spectrophotometric methods and kinetic analyses have been instrumental in determining the impact of various PTMs—such as S‑nitrosylation and phosphorylation—on GAPDH’s enzymatic parameters, thereby linking modification state to functional outcome (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4).

9.2 Proteomic Identification and Subcellular Fractionation
Mass spectrometry–based proteomic approaches have repeatedly confirmed the high abundance of GAPDH in diverse human cell types and have mapped its presence across multiple subcellular compartments. Proteomic data have revealed that GAPDH is predominantly found in cytoplasmic extracts; however, under conditions of oxidative stress or cytokine stimulation, GAPDH peptides have also been detected in nuclear fractions, mitochondrial preparations, and even extracellular vesicles (harshman2013characterizationofmultiple pages 22-22, chang2018proteomicinvestigatingthe pages 9-9, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14). Additionally, spectral count analyses from studies employing subcellular fractionation have provided quantitative support for its preferential cytoplasmic localization, while also documenting context-dependent shifts in its distribution under pathological conditions such as cancer (langston2013identificationofthe pages 37-39, langston2013identificationofthea pages 37-39, langston2013identificationoftheb pages 37-39).

9.3 Protein–Protein Interaction Studies
Co‑immunoprecipitation experiments, yeast two‑hybrid screens, and in vitro binding assays have been pivotal in delineating the extensive interactome of GAPDH. These studies have identified interactions with a range of proteins including SIAH1, HspB2, CHP1, TRAF2, TRAF3, and several components of the GAIT complex (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, khan2016proteinfunctiondiversity pages 84-88, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, hoopes2016acryabinteractomea pages 84-86). The biological significance of these interactions has been validated by mutagenesis experiments that demonstrate the necessity of specific post‑translational modifications for proper binding and subsequent signaling events (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13, hoopes2016acryabinteractomea pages 92-93).

9.4 Cellular and Animal Models
Studies using cultured cell lines and animal models have provided further insight into GAPDH’s multifunctionality. In neuronal cultures, for instance, oxidative stress induced by reactive oxygen or nitrogen species leads to GAPDH aggregation and nuclear translocation, events that are closely correlated with apoptotic cell death—a hallmark of neurodegenerative diseases (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, hoopes2016acryabinteractomea pages 91-92). In cancer models, upregulation of GAPDH expression under hypoxic conditions has been linked to enhanced glycolytic flux and tumor growth, and manipulation of its activity using small molecule inhibitors has demonstrated potential therapeutic benefit (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, kuo2021biomarkerdiscoveryin pages 8-9).
Furthermore, studies on sperm cells investigating the testis‑specific GAPDH isoform (GAPDHS) have revealed that oxidative modifications correlate with reduced sperm motility and male infertility, thereby linking GAPDH dysfunction to reproductive pathologies (gandini2017spermglyceraldehyde3phosphate pages 5-5, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13).

9.5 Structural and Mutagenesis Analyses
High‑resolution structural studies, including X‑ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, have elucidated the three-dimensional structure of GAPDH, revealing the conservation of its Rossmann fold and the configuration of its catalytic pocket. Mutagenesis experiments targeting key residues such as C152 and M46 have confirmed their critical roles in catalytic activity and susceptibility to oxidative modifications, which underlie the protein’s ability to transition between metabolic and non‑metabolic states (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4).

9.6 Integration of Multi‑Omics Data
The convergence of data from transcriptomics, proteomics, and metabolomics further establishes GAPDH as a nexus for cellular metabolism and stress response. Differential expression analyses in cancer versus normal tissues, combined with proteomic profiling of subcellular fractions, have underlined the importance of GAPDH in metabolic reprogramming and its modulation through PTMs under various physiological and pathological conditions (lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16, kuo2021biomarkerdiscoveryin pages 8-9).

Conclusion
GAPDH (UniProt ID: P04406) stands as a quintessential example of a multi‑functional enzyme that seamlessly integrates its role in core metabolic processes with a broad spectrum of regulatory functions in the cell. Its primary function—catalyzing a rate‑limiting step in glycolysis—is intricately linked with secondary roles that include regulation of apoptosis, autophagy, cytoskeletal architecture, and immune signaling. The protein’s dynamic subcellular localization—from the cytoplasm to the nucleus, mitochondria, and beyond—is orchestrated by a series of finely tuned post‑translational modifications that allow it to respond to cellular stress, hypoxia, and other external stimuli. This versatility is further underpinned by its conserved structural domains, comprising a Rossmann fold for NAD binding and a catalytic core that is highly sensitive to oxidative modifications.
In pathological contexts, alterations in GAPDH expression, localization, and modification state have been implicated in diverse disorders such as neurodegeneration, cancer, metabolic diseases, inflammatory conditions, and reproductive dysfunction. The intricate interplay between these roles is supported by a wealth of experimental evidence derived from biochemical assays, proteomic studies, structural and mutagenesis analyses, and in vivo disease models. Moreover, the evolutionary conservation of GAPDH underscores the fundamental importance of its functions across eukaryotic life.
Given its omnipresence and multifunctionality, GAPDH serves as a critical node linking cellular energy production to a host of regulatory networks that govern cell survival, death, and adaptation. Continued research into the precise mechanisms by which GAPDH transitions between its glycolytic and non‑glycolytic roles will not only refine our understanding of basic cellular physiology but also pave the way for novel therapeutic strategies targeting diseases where GAPDH dysfunction is a driving factor. In summary, the extensive experimental data and multi‑omic evidence discussed herein provide a robust framework for comprehensive Gene Ontology annotation, ensuring that the diverse biological roles of GAPDH are accurately represented and integrated within genomic databases (dominguez2016redoxproteomicprofiling pages 21-22, hoopes2016acryabinteractome pages 84-86, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4, khan2016proteinfunctiondiversity pages 84-88, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 6-8, gandini2017spermglyceraldehyde3phosphate pages 5-5, harshman2013characterizationofmultiple pages 22-22, chang2018proteomicinvestigatingthe pages 9-9, hoopes2016acryabinteractome pages 91-92, hoopes2016acryabinteractomea pages 84-86, hoopes2016acryabinteractomea pages 91-92, hoopes2016acryabinteractomea pages 92-93, khansarizadeh2016identificationofpossible pages 6-6, kuo2021biomarkerdiscoveryin pages 8-8, kuo2021biomarkerdiscoveryin pages 8-9, kuo2021biomarkerdiscoveryin pages 9-9, langston2013identificationofthe pages 37-39, langston2013identificationofthea pages 37-39, langston2013identificationoftheb pages 37-39, langston2013…thebinding pages 37-39, lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16).

Future perspectives in GAPDH research are likely to focus on further elucidating the structural determinants underlying its functional switching, the mechanistic intricacies of its post‑translational modifications, and the precise signaling networks modulated by its diverse interactions. As advances in mass spectrometry, molecular imaging, and systems biology enable more refined dissection of its interactome and subcellular dynamics, the full spectrum of GAPDH’s biological roles will become even clearer. This will not only facilitate the iterative refinement of GO annotations but also inform targeted interventions aimed at modulating GAPDH function in various diseases. Ultimately, GAPDH remains a central and indispensable player in cellular homeostasis whose study exemplifies the complex interdependence of metabolic and regulatory processes in human biology.

References

(dominguez2016redoxproteomicprofiling pages 21-22): Mayelín Domínguez, Eliandre de Oliveira, María Antonia Odena, Manuel Portero, Reinald Pamplona, and Isidro Ferrer. Redox proteomic profiling of neuroketal-adducted proteins in human brain: regional vulnerability at middle age increases in the elderly. Free radical biology & medicine, 95:1-15, Jun 2016. URL: https://doi.org/10.1016/j.freeradbiomed.2016.02.034, doi:10.1016/j.freeradbiomed.2016.02.034. This article has 37 citations and is from a peer-reviewed journal.
(hoopes2016acryabinteractome pages 84-86): WK Hoopes. A cryab interactome reveals clientele specificity and dysfunction of mutants associated with human disease. Unknown journal, 2016.
(lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 1-2): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.
(lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 2-4): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.
(hoopes2016acryabinteractome pages 92-93): WK Hoopes. A cryab interactome reveals clientele specificity and dysfunction of mutants associated with human disease. Unknown journal, 2016.
(lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 11-13): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.
(khan2016proteinfunctiondiversity pages 84-88): IK Khan. Protein function, diversity and functional interplay. Unknown journal, 2016.
(lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 13-14): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.
(lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 14-16): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.
(lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 4-6): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.
(harshman2013characterizationofmultiple pages 22-22): Sean W. Harshman, Alessandro Canella, Paul D. Ciarlariello, Alberto Rocci, Kitty Agarwal, Emily M. Smith, Tiffany Talabere, Yvonne A. Efebera, Craig C. Hofmeister, Don M. Benson, Michael E. Paulaitis, Michael A. Freitas, and Flavia Pichiorri. Characterization of multiple myeloma vesicles by label‐free relative quantitation. PROTEOMICS, 13:n/a-n/a, Oct 2013. URL: https://doi.org/10.1002/pmic.201300142, doi:10.1002/pmic.201300142. This article has 54 citations and is from a peer-reviewed journal.
(langston2013identificationoftheb pages 37-39): KM Langston. Identification of the binding partners for hspb2 and cryab reveals myofibril and mitochondrial protein interactions and non-redundant roles for small heat …. Unknown journal, 2013.
(hoopes2016acryabinteractome pages 91-92): WK Hoopes. A cryab interactome reveals clientele specificity and dysfunction of mutants associated with human disease. Unknown journal, 2016.
(kuo2021biomarkerdiscoveryin pages 8-9): Chin‐Ho Kuo, Meng‐Wei Lin, Yu‐Wei Hsu, Hsiu‐Chuan Chou, Li‐Hsun Lin, Ching‐Hsuan Law, Yi‐Chieh Lin, Ren‐Yu Hu, Wen‐Hung Kuo, Mei‐Lan Ko, Shing‐Jyh Chang, Ying‐Ray Lee, and Hong‐Lin Chan. Biomarker discovery in highly invasive lung cancer cell through proteomics approaches. Cell Biochemistry and Function, 39:367-379, Nov 2021. URL: https://doi.org/10.1002/cbf.3599, doi:10.1002/cbf.3599. This article has 6 citations and is from a peer-reviewed journal.
(hoopes2016acryabinteractomea pages 91-92): WK Hoopes. A cryab interactome reveals clientele specificity and dysfunction of mutants associated with human disease. Unknown journal, 2016.
(chang2018proteomicinvestigatingthe pages 9-9): Shing-Jyh Chang, En-Chi Liao, Hsin-Yueh Yeo, Wen-Hung Kuo, Hsin-Yi Chen, Yi-Ting Tsai, Yu-Shan Wei, Ying-Jen Chen, Yi-Shiuan Wang, Ji-Min Li, Chuan-Chi Shih, Chia-Hao Chan, Zih-Yin Lai, Hsiu-Chuan Chou, Yung-Jen Chuang, and Hong-Lin Chan. Proteomic investigating the cooperative lethal effect of egfr and mdm2 inhibitors on ovarian carcinoma. Archives of biochemistry and biophysics, 647:10-32, Jun 2018. URL: https://doi.org/10.1016/j.abb.2018.04.004, doi:10.1016/j.abb.2018.04.004. This article has 6 citations and is from a peer-reviewed journal.
(lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 6-8): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.
(hoopes2016acryabinteractomea pages 92-93): WK Hoopes. A cryab interactome reveals clientele specificity and dysfunction of mutants associated with human disease. Unknown journal, 2016.
(bharadwaj2013roleofthe pages 129-129): Arpita S. Bharadwaj, Binoy Appukuttan, Phillip A. Wilmarth, Yuzhen Pan, Andrew J. Stempel, Timothy J. Chipps, Eric E. Benedetti, David O. Zamora, Dongseok Choi, Larry L. David, and Justine R. Smith. Role of the retinal vascular endothelial cell in ocular disease. Progress in Retinal and Eye Research, 32:102-180, Jan 2013. URL: https://doi.org/10.1016/j.preteyeres.2012.08.004, doi:10.1016/j.preteyeres.2012.08.004. This article has 210 citations and is from a highest quality peer-reviewed journal.
(gandini2017spermglyceraldehyde3phosphate pages 5-5): Loredana Gandini, Donatella Paoli, Marianna Pelloni, Mariagrazia Gallo, Giulia Coltrinari, Francesco Lombardo, and Andrea Lenzi. Sperm glyceraldehyde 3-phosphate dehydrogenase gene expression in asthenozoospermic spermatozoa. Asian Journal of Andrology, 19:409, Jan 2017. URL: https://doi.org/10.4103/1008-682x.173934, doi:10.4103/1008-682x.173934. This article has 19 citations and is from a peer-reviewed journal.
(kuo2021biomarkerdiscoveryin pages 8-8): Chin‐Ho Kuo, Meng‐Wei Lin, Yu‐Wei Hsu, Hsiu‐Chuan Chou, Li‐Hsun Lin, Ching‐Hsuan Law, Yi‐Chieh Lin, Ren‐Yu Hu, Wen‐Hung Kuo, Mei‐Lan Ko, Shing‐Jyh Chang, Ying‐Ray Lee, and Hong‐Lin Chan. Biomarker discovery in highly invasive lung cancer cell through proteomics approaches. Cell Biochemistry and Function, 39:367-379, Nov 2021. URL: https://doi.org/10.1002/cbf.3599, doi:10.1002/cbf.3599. This article has 6 citations and is from a peer-reviewed journal.
(hoopes2016acryabinteractomea pages 84-86): WK Hoopes. A cryab interactome reveals clientele specificity and dysfunction of mutants associated with human disease. Unknown journal, 2016.
(lazarev2020glyceraldehyde3phosphatedehydrogenaseis pages 8-9): Vladimir F. Lazarev, Irina V. Guzhova, and Boris A. Margulis. Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target. Pharmaceutics, 12:416, May 2020. URL: https://doi.org/10.3390/pharmaceutics12050416, doi:10.3390/pharmaceutics12050416. This article has 79 citations and is from a poor quality or predatory journal.
(langston2013identificationofthe pages 37-39): KM Langston. Identification of the binding partners for hspb2 and cryab reveals myofibril and mitochondrial protein interactions and non-redundant roles for small heat …. Unknown journal, 2013.
(langston2013identificationofthea pages 37-39): KM Langston. Identification of the binding partners for hspb2 and cryab reveals myofibril and mitochondrial protein interactions and non-redundant roles for small heat …. Unknown journal, 2013.
(khansarizadeh2016identificationofpossible pages 6-6): M. Khansarizadeh, A. Mokhtarzadeh, M. Rashedinia, S. M. Taghdisi, P. Lari, K. Abnous, and M. Ramezani. Identification of possible cytotoxicity mechanism of polyethylenimine by proteomics analysis. Human & Experimental Toxicology, 35:377-387, Apr 2016. URL: https://doi.org/10.1177/0960327115591371, doi:10.1177/0960327115591371. This article has 93 citations and is from a peer-reviewed journal.
(kuo2021biomarkerdiscoveryin pages 9-9): Chin‐Ho Kuo, Meng‐Wei Lin, Yu‐Wei Hsu, Hsiu‐Chuan Chou, Li‐Hsun Lin, Ching‐Hsuan Law, Yi‐Chieh Lin, Ren‐Yu Hu, Wen‐Hung Kuo, Mei‐Lan Ko, Shing‐Jyh Chang, Ying‐Ray Lee, and Hong‐Lin Chan. Biomarker discovery in highly invasive lung cancer cell through proteomics approaches. Cell Biochemistry and Function, 39:367-379, Nov 2021. URL: https://doi.org/10.1002/cbf.3599, doi:10.1002/cbf.3599. This article has 6 citations and is from a peer-reviewed journal.
(langston2013…thebinding pages 37-39): KM Langston. … the binding partners for hspb2 and cryab reveals myofibril and mitochondrial protein interactions and non-redundant roles for small heat shock proteins. Unknown journal, 2013.

📄 View Raw YAML

id: P04406
gene_symbol: GAPDH
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) is a multifunctional protein best known for its role in glycolysis, catalyzing the oxidation and phosphorylation of glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate. Beyond metabolism, GAPDH has extraordinary moonlighting functions including roles in transcription, apoptosis, membrane trafficking, cytoskeletal dynamics, and immune responses. It localizes to multiple cellular compartments (cytosol, nucleus, membrane, mitochondria) and its diverse functions are regulated by post-translational modifications including S-nitrosylation, acetylation, and oxidation. This context-dependent multifunctionality makes GAPDH a prime example of protein moonlighting, where a single protein performs multiple unrelated functions depending on cellular conditions and localization.
existing_annotations:
- term:
    id: GO:0006096
    label: glycolytic process
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: Core metabolic function of GAPDH, well-established
    action: ACCEPT
    supported_by:
    - reference_id: file:human/GAPDH/GAPDH-falcon-research.md
      supporting_text: See deep research file for comprehensive analysis
- term:
    id: GO:0004365
    label: glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: Primary enzymatic activity, catalyzing G3P to 1,3-BPG conversion
    action: ACCEPT
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: Primary localization for glycolytic function
    action: ACCEPT
- term:
    id: GO:0002376
    label: immune system process
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: Too general; GAPDH has specific roles in innate immunity via TRAF2/3
    action: MODIFY
    proposed_replacement_terms:
    - id: GO:0045087
      label: innate immune response
- term:
    id: GO:0004365
    label: glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity annotation for GAPDH.
    action: ACCEPT
    reason: Glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity is the primary catalytic function of GAPDH. Multiple evidence codes support this annotation.
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: GAPDH translocates to the nucleus under stress conditions where it functions as a S-nitrosylase to regulate apoptosis by modifying nuclear proteins through S-nitrosylation.
    action: ACCEPT
    reason: Nuclear localization is essential for GAPDH's moonlighting function as a peptidyl-cysteine S-nitrosylase that regulates apoptotic processes by S-nitrosylating nuclear target proteins.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: cytosol annotation for GAPDH.
    action: ACCEPT
    reason: Cytosol is the primary localization for GAPDH's glycolytic function. Multiple evidence codes support this annotation.
- term:
    id: GO:0005856
    label: cytoskeleton
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: Interacts with microtubules via CHP1, moonlighting function
    action: KEEP_AS_NON_CORE
- term:
    id: GO:0006006
    label: glucose metabolic process
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  review:
    summary: Core metabolic function, part of glycolysis
    action: ACCEPT
- term:
    id: GO:0006096
    label: glycolytic process
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: glycolytic process annotation for GAPDH.
    action: ACCEPT
    reason: Glycolytic process is the core metabolic pathway for GAPDH. Multiple evidence codes support this annotation.
- term:
    id: GO:0006417
    label: regulation of translation
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: Component of GAIT complex, regulates translation of inflammatory mRNAs
    action: KEEP_AS_NON_CORE
- term:
    id: GO:0006915
    label: apoptotic process
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: Nuclear translocation under stress activates p53-dependent apoptosis
    action: KEEP_AS_NON_CORE
- term:
    id: GO:0016020
    label: membrane
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: Too general - specify plasma membrane or other specific membranes
    action: REMOVE
- term:
    id: GO:0016491
    label: oxidoreductase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: Too general; specific activity is glyceraldehyde-3-phosphate dehydrogenase
    action: REMOVE
- term:
    id: GO:0016620
    label: oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  review:
    summary: Parent term of GO:0004365, acceptable but redundant
    action: REMOVE
- term:
    id: GO:0016740
    label: transferase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: Too general and imprecise for GAPDH function
    action: REMOVE
- term:
    id: GO:0035605
    label: peptidyl-cysteine S-nitrosylase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000116
  review:
    summary: Important moonlighting function, S-nitrosylates nuclear targets like SIRT1
    action: KEEP_AS_NON_CORE
- term:
    id: GO:0045087
    label: innate immune response
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: Promotes NF-kB activation and type I interferon via TRAF2/3 interactions
    action: KEEP_AS_NON_CORE
- term:
    id: GO:0048471
    label: perinuclear region of cytoplasm
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: Can localize here during nuclear translocation
    action: KEEP_AS_NON_CORE
- term:
    id: GO:0050661
    label: NADP binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  review:
    summary: GAPDH uses NAD+ not NADP+, likely incorrect
    action: REMOVE
- term:
    id: GO:0051287
    label: NAD binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  review:
    summary: Essential for catalytic activity, NAD+ is the cofactor
    action: ACCEPT
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:16169070
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:16169070
      supporting_text: 'A human protein-protein interaction network: a resource for annotating the proteome.'
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:16799092
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:16799092
      supporting_text: Epub 2006 Jun 23. Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA).
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:17353931
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:17353931
      supporting_text: Large-scale mapping of human protein-protein interactions by mass spectrometry.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:17500595
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:17500595
      supporting_text: Huntingtin interacting proteins are genetic modifiers of neurodegeneration.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:20029029
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:20029029
      supporting_text: Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:20392205
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:20392205
      supporting_text: Loose interaction between glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate kinase revealed by fluorescence resonance energy transfer-fluorescence lifetime imaging microscopy in living cells.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:20849852
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:20849852
      supporting_text: Epub 2010 Sep 16. Proliferating cell nuclear antigen in the cytoplasm interacts with components of glycolysis and cancer.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:21044950
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:21044950
      supporting_text: Epub 2010 Nov 2. Genome-wide YFP fluorescence complementation screen identifies new regulators for telomere signaling in human cells.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:23348613
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:23348613
      supporting_text: Prolyl oligopeptidase is a glyceraldehyde-3-phosphate dehydrogenase-binding protein that regulates genotoxic stress-induced cell death.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:24658140
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:24658140
      supporting_text: The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:25417112
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:25417112
      supporting_text: Oct 16. Target-selective protein S-nitrosylation by sequence motif recognition.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:28514442
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:28514442
      supporting_text: Architecture of the human interactome defines protein communities and disease networks.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:29028794
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:29028794
      supporting_text: eCollection 2017 Oct.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:29128334
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:29128334
      supporting_text: 2017 Nov 8. A Map of Human Mitochondrial Protein Interactions Linked to Neurodegeneration Reveals New Mechanisms of Redox Homeostasis and NF-κB Signaling.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:31980649
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:31980649
      supporting_text: Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRAS(G13D).
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:32814053
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:32814053
      supporting_text: Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:33961781
  review:
    summary: Non-specific annotation - need more specific binding terms
    action: REMOVE
    supported_by:
    - reference_id: PMID:33961781
      supporting_text: 2021 May 6. Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.
- term:
    id: GO:0042802
    label: identical protein binding
  evidence_type: IPI
  original_reference_id: PMID:20392205
  review:
    summary: Forms homotetramers, essential for enzymatic activity
    action: ACCEPT
    supported_by:
    - reference_id: PMID:20392205
      supporting_text: Loose interaction between glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate kinase revealed by fluorescence resonance energy transfer-fluorescence lifetime imaging microscopy in living cells.
- term:
    id: GO:0042802
    label: identical protein binding
  evidence_type: IPI
  original_reference_id: PMID:21988832
  review:
    summary: identical protein binding annotation for GAPDH.
    action: ACCEPT
    reason: GAPDH forms homotetramers (identical protein binding) which is essential for its catalytic activity. Multiple evidence codes support this annotation.
    supported_by:
    - reference_id: PMID:21988832
      supporting_text: Toward an understanding of the protein interaction network of the human liver.
- term:
    id: GO:0004365
    label: glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity
  evidence_type: NAS
  original_reference_id: PMID:3170585
  review:
    summary: glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity annotation for GAPDH.
    action: ACCEPT
    reason: Glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity is the primary catalytic function of GAPDH. Multiple evidence codes support this annotation.
    supported_by:
    - reference_id: PMID:3170585
      supporting_text: Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: cytosol annotation for GAPDH.
    action: ACCEPT
    reason: Cytosol is the primary localization for GAPDH's glycolytic function. Multiple evidence codes support this annotation.
- term:
    id: GO:0061621
    label: canonical glycolysis
  evidence_type: IDA
  original_reference_id: PMID:3170585
  review:
    summary: Direct experimental evidence for glycolytic function
    action: ACCEPT
    supported_by:
    - reference_id: PMID:3170585
      supporting_text: Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: IDA
  original_reference_id: GO_REF:0000052
  review:
    summary: cytosol annotation for GAPDH.
    action: ACCEPT
    reason: Cytosol is the primary localization for GAPDH's glycolytic function. Multiple evidence codes support this annotation.
- term:
    id: GO:0005886
    label: plasma membrane
  evidence_type: IDA
  original_reference_id: GO_REF:0000052
  review:
    summary: GAPDH can localize to membrane in certain contexts
    action: KEEP_AS_NON_CORE
- term:
    id: GO:0031965
    label: nuclear membrane
  evidence_type: IDA
  original_reference_id: GO_REF:0000052
  review:
    summary: Can associate with nuclear membrane during translocation
    action: KEEP_AS_NON_CORE
- term:
    id: GO:0035605
    label: peptidyl-cysteine S-nitrosylase activity
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: peptidyl-cysteine S-nitrosylase activity annotation for GAPDH.
    action: KEEP_AS_NON_CORE
    reason: Peptidyl-cysteine S-nitrosylase activity is a regulatory function of GAPDH, not its core catalytic activity.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:23332158
  review:
    summary: Non-specific - specific interaction with TRAF2 documented
    action: REMOVE
    supported_by:
    - reference_id: PMID:23332158
      supporting_text: Epub 2013 Jan 16. NleB, a bacterial effector with glycosyltransferase activity, targets GAPDH function to inhibit NF-κB activation.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:27387501
  review:
    summary: Non-specific - specific interaction with TRAF3 documented
    action: REMOVE
    supported_by:
    - reference_id: PMID:27387501
      supporting_text: 2016 Jul 7. Citrobacter rodentium NleB Protein Inhibits Tumor Necrosis Factor (TNF) Receptor-associated Factor 3 (TRAF3) Ubiquitination to Reduce Host Type I Interferon Production.
- term:
    id: GO:0032481
    label: positive regulation of type I interferon production
  evidence_type: IDA
  original_reference_id: PMID:27387501
  review:
    summary: Via TRAF3 interaction, moonlighting innate immune function
    action: KEEP_AS_NON_CORE
    supported_by:
    - reference_id: PMID:27387501
      supporting_text: 2016 Jul 7. Citrobacter rodentium NleB Protein Inhibits Tumor Necrosis Factor (TNF) Receptor-associated Factor 3 (TRAF3) Ubiquitination to Reduce Host Type I Interferon Production.
- term:
    id: GO:0043123
    label: positive regulation of canonical NF-kappaB signal transduction
  evidence_type: IDA
  original_reference_id: PMID:23332158
  review:
    summary: Via TRAF2 interaction, moonlighting innate immune function
    action: KEEP_AS_NON_CORE
    supported_by:
    - reference_id: PMID:23332158
      supporting_text: Epub 2013 Jan 16. NleB, a bacterial effector with glycosyltransferase activity, targets GAPDH function to inhibit NF-κB activation.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:23355646
  review:
    summary: Non-specific annotation
    action: REMOVE
    supported_by:
    - reference_id: PMID:23355646
      supporting_text: Identification of sperm head proteins involved in zona pellucida binding.
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IDA
  original_reference_id: PMID:24507776
  review:
    summary: Primary localization, more specific as cytosol
    action: ACCEPT
    supported_by:
    - reference_id: PMID:24507776
      supporting_text: ERCC6L2 mutations link a distinct bone-marrow-failure syndrome to DNA repair and mitochondrial function.
- term:
    id: GO:0001819
    label: positive regulation of cytokine production
  evidence_type: IDA
  original_reference_id: PMID:22832495
  review:
    summary: Antimicrobial moonlighting function, extracellular GAPDH
    action: KEEP_AS_NON_CORE
    supported_by:
    - reference_id: PMID:22832495
      supporting_text: 2012 Jul 26. A peptide derived from the highly conserved protein GAPDH is involved in tissue protection by different antifungal strategies and epithelial immunomodulation.
- term:
    id: GO:0010951
    label: negative regulation of endopeptidase activity
  evidence_type: IDA
  original_reference_id: PMID:22832495
  review:
    summary: Antimicrobial moonlighting function
    action: KEEP_AS_NON_CORE
    supported_by:
    - reference_id: PMID:22832495
      supporting_text: 2012 Jul 26. A peptide derived from the highly conserved protein GAPDH is involved in tissue protection by different antifungal strategies and epithelial immunomodulation.
- term:
    id: GO:0019828
    label: aspartic-type endopeptidase inhibitor activity
  evidence_type: IDA
  original_reference_id: PMID:22832495
  review:
    summary: Antimicrobial moonlighting activity against pathogens
    action: KEEP_AS_NON_CORE
    supported_by:
    - reference_id: PMID:22832495
      supporting_text: 2012 Jul 26. A peptide derived from the highly conserved protein GAPDH is involved in tissue protection by different antifungal strategies and epithelial immunomodulation.
- term:
    id: GO:0031640
    label: killing of cells of another organism
  evidence_type: IDA
  original_reference_id: PMID:22832495
  review:
    summary: Antimicrobial moonlighting function
    action: KEEP_AS_NON_CORE
    supported_by:
    - reference_id: PMID:22832495
      supporting_text: 2012 Jul 26. A peptide derived from the highly conserved protein GAPDH is involved in tissue protection by different antifungal strategies and epithelial immunomodulation.
- term:
    id: GO:0050832
    label: defense response to fungus
  evidence_type: IDA
  original_reference_id: PMID:22832495
  review:
    summary: Extracellular GAPDH has antifungal activity
    action: KEEP_AS_NON_CORE
    supported_by:
    - reference_id: PMID:22832495
      supporting_text: 2012 Jul 26. A peptide derived from the highly conserved protein GAPDH is involved in tissue protection by different antifungal strategies and epithelial immunomodulation.
- term:
    id: GO:0051873
    label: obsolete killing by host of symbiont cells
  evidence_type: IDA
  original_reference_id: PMID:22832495
  review:
    summary: Antimicrobial moonlighting function
    action: KEEP_AS_NON_CORE
    supported_by:
    - reference_id: PMID:22832495
      supporting_text: 2012 Jul 26. A peptide derived from the highly conserved protein GAPDH is involved in tissue protection by different antifungal strategies and epithelial immunomodulation.
- term:
    id: GO:0061844
    label: antimicrobial humoral immune response mediated by antimicrobial peptide
  evidence_type: IDA
  original_reference_id: PMID:22832495
  review:
    summary: GAPDH can act as antimicrobial protein extracellularly
    action: KEEP_AS_NON_CORE
    supported_by:
    - reference_id: PMID:22832495
      supporting_text: 2012 Jul 26. A peptide derived from the highly conserved protein GAPDH is involved in tissue protection by different antifungal strategies and epithelial immunomodulation.
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IDA
  original_reference_id: PMID:28404743
  review:
    summary: nucleus annotation for GAPDH.
    action: ACCEPT
    reason: GAPDH is present in the nucleus where it has non-glycolytic functions. Multiple evidence codes support this localization.
    supported_by:
    - reference_id: PMID:28404743
      supporting_text: Nuclear complex of glyceraldehyde-3-phosphate dehydrogenase and DNA repair enzyme apurinic/apyrimidinic endonuclease I protect smooth muscle cells against oxidant-induced cell death.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: IDA
  original_reference_id: PMID:28404743
  review:
    summary: cytosol annotation for GAPDH.
    action: ACCEPT
    reason: Cytosol is the primary localization for GAPDH's glycolytic function. Multiple evidence codes support this annotation.
    supported_by:
    - reference_id: PMID:28404743
      supporting_text: Nuclear complex of glyceraldehyde-3-phosphate dehydrogenase and DNA repair enzyme apurinic/apyrimidinic endonuclease I protect smooth muscle cells against oxidant-induced cell death.
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IDA
  original_reference_id: PMID:11785981
  review:
    summary: cytoplasm annotation for GAPDH.
    action: ACCEPT
    reason: Cytoplasm is a core localization for GAPDH. Multiple evidence codes support this annotation.
    supported_by:
    - reference_id: PMID:11785981
      supporting_text: HSP90, HSP70, and GAPDH directly interact with the cytoplasmic domain of macrophage scavenger receptors.
- term:
    id: GO:0097718
    label: disordered domain specific binding
  evidence_type: IPI
  original_reference_id: PMID:11785981
  review:
    summary: Duplicate cytosol annotation
    action: REMOVE
    supported_by:
    - reference_id: PMID:11785981
      supporting_text: HSP90, HSP70, and GAPDH directly interact with the cytoplasmic domain of macrophage scavenger receptors.
- term:
    id: GO:0016241
    label: regulation of macroautophagy
  evidence_type: TAS
  original_reference_id: PMID:26626483
  review:
    summary: Duplicate cytosol annotation
    action: REMOVE
    supported_by:
    - reference_id: PMID:26626483
      supporting_text: 2015 Nov 25. AMPK-Dependent Phosphorylation of GAPDH Triggers Sirt1 Activation and Is Necessary for Autophagy upon Glucose Starvation.
- term:
    id: GO:0070062
    label: extracellular exosome
  evidence_type: HDA
  original_reference_id: PMID:12519789
  review:
    summary: extracellular exosome annotation for GAPDH.
    action: ACCEPT
    reason: GAPDH is found in extracellular exosomes. Multiple high-throughput studies support this localization.
    supported_by:
    - reference_id: PMID:12519789
      supporting_text: 2003 Jan 7. Proteomic and biochemical analyses of human B cell-derived exosomes.
- term:
    id: GO:0070062
    label: extracellular exosome
  evidence_type: HDA
  original_reference_id: PMID:11487543
  review:
    summary: extracellular exosome annotation for GAPDH.
    action: ACCEPT
    reason: GAPDH is found in extracellular exosomes. Multiple high-throughput studies support this localization.
    supported_by:
    - reference_id: PMID:11487543
      supporting_text: Intestinal epithelial cells secrete exosome-like vesicles.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: IDA
  original_reference_id: PMID:24101517
  review:
    summary: cytosol annotation for GAPDH.
    action: ACCEPT
    reason: Cytosol is the primary localization for GAPDH's glycolytic function. Multiple evidence codes support this annotation.
    supported_by:
    - reference_id: PMID:24101517
      supporting_text: Mitochondrial disulfide relay mediates translocation of p53 and partitions its subcellular activity.
- term:
    id: GO:0070062
    label: extracellular exosome
  evidence_type: HDA
  original_reference_id: PMID:23533145
  review:
    summary: extracellular exosome annotation for GAPDH.
    action: ACCEPT
    reason: GAPDH is found in extracellular exosomes. Multiple high-throughput studies support this localization.
    supported_by:
    - reference_id: PMID:23533145
      supporting_text: 2013 Apr 23. In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.
- term:
    id: GO:0031982
    label: vesicle
  evidence_type: HDA
  original_reference_id: PMID:19190083
  review:
    summary: Duplicate cytosol annotation
    action: REMOVE
    supported_by:
    - reference_id: PMID:19190083
      supporting_text: 'Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense.'
- term:
    id: GO:0016020
    label: membrane
  evidence_type: HDA
  original_reference_id: PMID:19946888
  review:
    summary: Duplicate cytosol annotation
    action: REMOVE
    supported_by:
    - reference_id: PMID:19946888
      supporting_text: Defining the membrane proteome of NK cells.
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: HDA
  original_reference_id: PMID:21630459
  review:
    summary: nucleus annotation for GAPDH.
    action: ACCEPT
    reason: GAPDH is present in the nucleus where it has non-glycolytic functions. Multiple evidence codes support this localization.
    supported_by:
    - reference_id: PMID:21630459
      supporting_text: Jun 1. Proteomic characterization of the human sperm nucleus.
- term:
    id: GO:0097452
    label: GAIT complex
  evidence_type: IDA
  original_reference_id: PMID:15479637
  review:
    summary: GAIT complex annotation for GAPDH.
    action: ACCEPT
    reason: GAPDH is a component of the GAIT complex involved in translational regulation. Multiple evidence codes support this annotation.
    supported_by:
    - reference_id: PMID:15479637
      supporting_text: 'Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific silencing of translation.'
- term:
    id: GO:0097452
    label: GAIT complex
  evidence_type: IDA
  original_reference_id: PMID:23071094
  review:
    summary: GAPDH is a key component of the GAIT (gamma interferon-activated inhibitor of translation) complex, which regulates inflammatory mRNA translation through its RNA binding activity.
    action: ACCEPT
    reason: GAIT complex localization is essential for GAPDH's moonlighting function as an RNA-binding protein that regulates post-transcriptional control of inflammatory gene expression.
    supported_by:
    - reference_id: PMID:23071094
      supporting_text: Oct 15. Heterotrimeric GAIT complex drives transcript-selective translation inhibition in murine macrophages.
- term:
    id: GO:0070062
    label: extracellular exosome
  evidence_type: HDA
  original_reference_id: PMID:19199708
  review:
    summary: GAPDH is secreted in extracellular exosomes where it exhibits antimicrobial activity, particularly against fungal pathogens, representing a moonlighting function distinct from its glycolytic role.
    action: ACCEPT
    reason: Extracellular exosome localization enables GAPDH's moonlighting antimicrobial function, allowing the protein to act as an aspartic-type endopeptidase inhibitor in host defense against fungal infections.
    supported_by:
    - reference_id: PMID:19199708
      supporting_text: Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).
- term:
    id: GO:0070062
    label: extracellular exosome
  evidence_type: HDA
  original_reference_id: PMID:19056867
  review:
    summary: extracellular exosome annotation for GAPDH.
    action: ACCEPT
    reason: GAPDH is found in extracellular exosomes. Multiple high-throughput studies support this localization.
    supported_by:
    - reference_id: PMID:19056867
      supporting_text: 2008 Dec 3. Large-scale proteomics and phosphoproteomics of urinary exosomes.
- term:
    id: GO:0070062
    label: extracellular exosome
  evidence_type: HDA
  original_reference_id: PMID:20458337
  review:
    summary: extracellular exosome annotation for GAPDH.
    action: ACCEPT
    reason: GAPDH is found in extracellular exosomes. Multiple high-throughput studies support this localization.
    supported_by:
    - reference_id: PMID:20458337
      supporting_text: 2010 May 11. MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-70449
  review:
    summary: cytosol annotation for GAPDH.
    action: ACCEPT
    reason: Cytosol is the primary localization for GAPDH's glycolytic function. Multiple evidence codes support this annotation.
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-70482
  review:
    summary: cytosol annotation for GAPDH.
    action: ACCEPT
    reason: Cytosol is the primary localization for GAPDH's glycolytic function. Multiple evidence codes support this annotation.
- term:
    id: GO:0017148
    label: negative regulation of translation
  evidence_type: IMP
  original_reference_id: PMID:15479637
  review:
    summary: Duplicate cytosol annotation
    action: REMOVE
    supported_by:
    - reference_id: PMID:15479637
      supporting_text: 'Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific silencing of translation.'
- term:
    id: GO:0017148
    label: negative regulation of translation
  evidence_type: IDA
  original_reference_id: PMID:23071094
  review:
    summary: Duplicate cytosol annotation - already reviewed
    action: REMOVE
    supported_by:
    - reference_id: PMID:23071094
      supporting_text: Oct 15. Heterotrimeric GAIT complex drives transcript-selective translation inhibition in murine macrophages.
- term:
    id: GO:0071346
    label: cellular response to type II interferon
  evidence_type: IDA
  original_reference_id: PMID:15479637
  review:
    summary: Duplicate cytosol annotation - already reviewed
    action: REMOVE
    supported_by:
    - reference_id: PMID:15479637
      supporting_text: 'Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific silencing of translation.'
- term:
    id: GO:1990904
    label: ribonucleoprotein complex
  evidence_type: IDA
  original_reference_id: PMID:15479637
  review:
    summary: Duplicate cytosol annotation - already reviewed
    action: REMOVE
    supported_by:
    - reference_id: PMID:15479637
      supporting_text: 'Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific silencing of translation.'
- term:
    id: GO:0070062
    label: extracellular exosome
  evidence_type: HDA
  original_reference_id: PMID:21362503
  review:
    summary: extracellular exosome annotation for GAPDH.
    action: ACCEPT
    reason: GAPDH is found in extracellular exosomes. Multiple high-throughput studies support this localization.
    supported_by:
    - reference_id: PMID:21362503
      supporting_text: Epub 2011 Mar 8. Protein profile of exosomes from trabecular meshwork cells.
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: cytoplasm annotation for GAPDH.
    action: ACCEPT
    reason: Cytoplasm is a core localization for GAPDH. Multiple evidence codes support this annotation.
- term:
    id: GO:0015630
    label: microtubule cytoskeleton
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: Duplicate cytosol annotation - already reviewed
    action: REMOVE
- term:
    id: GO:0000226
    label: microtubule cytoskeleton organization
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: Duplicate cytosol annotation - already reviewed
    action: REMOVE
- term:
    id: GO:0008017
    label: microtubule binding
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: Duplicate cytosol annotation - already reviewed
    action: REMOVE
- term:
    id: GO:0005811
    label: lipid droplet
  evidence_type: IDA
  original_reference_id: PMID:14741744
  review:
    summary: Duplicate cytosol annotation - already reviewed
    action: REMOVE
    supported_by:
    - reference_id: PMID:14741744
      supporting_text: Identification of major proteins in the lipid droplet-enriched fraction isolated from the human hepatocyte cell line HuH7.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:11724794
  review:
    summary: Duplicate cytosol annotation - already reviewed
    action: REMOVE
    supported_by:
    - reference_id: PMID:11724794
      supporting_text: Nov 27. Glyceraldehyde-3-phosphate dehydrogenase is phosphorylated by protein kinase Ciota /lambda and plays a role in microtubule dynamics in the early secretory pathway.
- term:
    id: GO:0004365
    label: glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity annotation for GAPDH.
    action: ACCEPT
    reason: Glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity is the primary catalytic function of GAPDH. Multiple evidence codes support this annotation.
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: nucleus annotation for GAPDH.
    action: ACCEPT
    reason: GAPDH is present in the nucleus where it has non-glycolytic functions. Multiple evidence codes support this localization.
- term:
    id: GO:0035606
    label: peptidyl-cysteine S-trans-nitrosylation
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: Duplicate cytosol annotation - already reviewed
    action: REMOVE
- term:
    id: GO:0050821
    label: protein stabilization
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: Duplicate cytosol annotation - already reviewed
    action: REMOVE
- term:
    id: GO:0051402
    label: neuron apoptotic process
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: Duplicate cytosol annotation - already reviewed
    action: REMOVE
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:15628863
  review:
    summary: Duplicate cytosol annotation - already reviewed
    action: REMOVE
    supported_by:
    - reference_id: PMID:15628863
      supporting_text: Oxidative stress-responsive intracellular regulation specific for the angiostatic form of human tryptophanyl-tRNA synthetase.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:17540579
  review:
    summary: Duplicate cytosol annotation - already reviewed
    action: REMOVE
    supported_by:
    - reference_id: PMID:17540579
      supporting_text: Epub 2007 Apr 20. A mutation in human VAP-B--MSP domain, present in ALS patients, affects the interaction with other cellular proteins.
- term:
    id: GO:0004365
    label: glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity
  evidence_type: NAS
  original_reference_id: PMID:7030790
  review:
    summary: glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity annotation for GAPDH.
    action: ACCEPT
    reason: Glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity is the primary catalytic function of GAPDH. Multiple evidence codes support this annotation.
    supported_by:
    - reference_id: PMID:7030790
      supporting_text: The complete amino acid sequence of human muscle glyceraldehyde 3-phosphate dehydrogenase.
- term:
    id: GO:0003723
    label: RNA binding
  evidence_type: NAS
  review:
    summary: Added to align core_functions with existing annotations.
    action: NEW
    reason: Core function term not present in existing_annotations.
    supported_by:
    - reference_id: PMID:23071094
      supporting_text: However, the triad of Ser(999)-phosphorylated EPRS, Ser(77)-phosphorylated L13a, and GAPDH forms a functional GAIT complex that inhibits translation of GAIT target mRNAs.
references:
- id: GO_REF:0000002
  title: Gene Ontology annotation through association of InterPro records with GO terms.
  findings: []
- id: GO_REF:0000024
  title: Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence similarity.
  findings: []
- id: GO_REF:0000033
  title: Annotation inferences using phylogenetic trees
  findings: []
- id: GO_REF:0000043
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping
  findings: []
- id: GO_REF:0000044
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt.
  findings: []
- id: GO_REF:0000052
  title: Gene Ontology annotation based on curation of immunofluorescence data
  findings: []
- id: GO_REF:0000116
  title: Automatic Gene Ontology annotation based on Rhea mapping.
  findings: []
- id: GO_REF:0000120
  title: Combined Automated Annotation using Multiple IEA Methods.
  findings: []
- id: PMID:11487543
  title: Intestinal epithelial cells secrete exosome-like vesicles.
  findings: []
- id: PMID:11724794
  title: Glyceraldehyde-3-phosphate dehydrogenase is phosphorylated by protein kinase Ciota /lambda and plays a role in microtubule dynamics in the early secretory pathway.
  findings: []
- id: PMID:11785981
  title: HSP90, HSP70, and GAPDH directly interact with the cytoplasmic domain of macrophage scavenger receptors.
  findings: []
- id: PMID:12519789
  title: Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation.
  findings: []
- id: PMID:14741744
  title: Identification of major proteins in the lipid droplet-enriched fraction isolated from the human hepatocyte cell line HuH7.
  findings: []
- id: PMID:15479637
  title: 'Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific silencing of translation.'
  findings: []
- id: PMID:15628863
  title: Oxidative stress-responsive intracellular regulation specific for the angiostatic form of human tryptophanyl-tRNA synthetase.
  findings: []
- id: PMID:16169070
  title: 'A human protein-protein interaction network: a resource for annotating the proteome.'
  findings: []
- id: PMID:16799092
  title: Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA).
  findings: []
- id: PMID:17353931
  title: Large-scale mapping of human protein-protein interactions by mass spectrometry.
  findings: []
- id: PMID:17500595
  title: Huntingtin interacting proteins are genetic modifiers of neurodegeneration.
  findings: []
- id: PMID:17540579
  title: A mutation in human VAP-B--MSP domain, present in ALS patients, affects the interaction with other cellular proteins.
  findings: []
- id: PMID:19056867
  title: Large-scale proteomics and phosphoproteomics of urinary exosomes.
  findings: []
- id: PMID:19190083
  title: 'Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense.'
  findings: []
- id: PMID:19199708
  title: Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).
  findings: []
- id: PMID:19946888
  title: Defining the membrane proteome of NK cells.
  findings: []
- id: PMID:20029029
  title: Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6.
  findings: []
- id: PMID:20392205
  title: Loose interaction between glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate kinase revealed by fluorescence resonance energy transfer-fluorescence lifetime imaging microscopy in living cells.
  findings: []
- id: PMID:20458337
  title: MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis.
  findings: []
- id: PMID:20849852
  title: Proliferating cell nuclear antigen in the cytoplasm interacts with components of glycolysis and cancer.
  findings: []
- id: PMID:21044950
  title: Genome-wide YFP fluorescence complementation screen identifies new regulators for telomere signaling in human cells.
  findings: []
- id: PMID:21362503
  title: Protein profile of exosomes from trabecular meshwork cells.
  findings: []
- id: PMID:21630459
  title: Proteomic characterization of the human sperm nucleus.
  findings: []
- id: PMID:21988832
  title: Toward an understanding of the protein interaction network of the human liver.
  findings: []
- id: PMID:22832495
  title: A peptide derived from the highly conserved protein GAPDH is involved in tissue protection by different antifungal strategies and epithelial immunomodulation.
  findings: []
- id: PMID:23071094
  title: Heterotrimeric GAIT complex drives transcript-selective translation inhibition in murine macrophages.
  findings: []
- id: PMID:23332158
  title: NleB, a bacterial effector with glycosyltransferase activity, targets GAPDH function to inhibit NF-κB activation.
  findings: []
- id: PMID:23348613
  title: Prolyl oligopeptidase is a glyceraldehyde-3-phosphate dehydrogenase-binding protein that regulates genotoxic stress-induced cell death.
  findings: []
- id: PMID:23355646
  title: Identification of sperm head proteins involved in zona pellucida binding.
  findings: []
- id: PMID:23533145
  title: In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.
  findings: []
- id: PMID:24101517
  title: Mitochondrial disulfide relay mediates translocation of p53 and partitions its subcellular activity.
  findings: []
- id: PMID:24507776
  title: ERCC6L2 mutations link a distinct bone-marrow-failure syndrome to DNA repair and mitochondrial function.
  findings: []
- id: PMID:24658140
  title: The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells.
  findings: []
- id: PMID:25417112
  title: Target-selective protein S-nitrosylation by sequence motif recognition.
  findings: []
- id: PMID:26626483
  title: AMPK-Dependent Phosphorylation of GAPDH Triggers Sirt1 Activation and Is Necessary for Autophagy upon Glucose Starvation.
  findings: []
- id: PMID:27387501
  title: Citrobacter rodentium NleB Protein Inhibits Tumor Necrosis Factor (TNF) Receptor-associated Factor 3 (TRAF3) Ubiquitination to Reduce Host Type I Interferon Production.
  findings: []
- id: PMID:28404743
  title: Nuclear complex of glyceraldehyde-3-phosphate dehydrogenase and DNA repair enzyme apurinic/apyrimidinic endonuclease I protect smooth muscle cells against oxidant-induced cell death.
  findings: []
- id: PMID:28514442
  title: Architecture of the human interactome defines protein communities and disease networks.
  findings: []
- id: PMID:29028794
  title: Condensin II and GAIT complexes cooperate to restrict LINE-1 retrotransposition in epithelial cells.
  findings: []
- id: PMID:29128334
  title: A Map of Human Mitochondrial Protein Interactions Linked to Neurodegeneration Reveals New Mechanisms of Redox Homeostasis and NF-κB Signaling.
  findings: []
- id: PMID:3170585
  title: Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene.
  findings: []
- id: PMID:31980649
  title: Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRAS(G13D).
  findings: []
- id: PMID:32814053
  title: Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains.
  findings: []
- id: PMID:33961781
  title: Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.
  findings: []
- id: PMID:7030790
  title: The complete amino acid sequence of human muscle glyceraldehyde 3-phosphate dehydrogenase.
  findings: []
- id: Reactome:R-HSA-70449
  title: GADPH tetramer dehydrogenates GA3P
  findings: []
- id: Reactome:R-HSA-70482
  title: GAPDH tetramers reduce 1,3BPG to GA3P
  findings: []
- id: file:human/GAPDH/GAPDH-falcon-research.md
  title: Deep research on GAPDH function
  findings: []
core_functions:
- molecular_function:
    id: GO:0004365
    label: glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity
  directly_involved_in:
  - id: GO:0061621
    label: canonical glycolysis
  locations:
  - id: GO:0005829
    label: cytosol
  description: Primary glycolytic function - catalyzes oxidative phosphorylation of G3P to 1,3-BPG
- molecular_function:
    id: GO:0035605
    label: peptidyl-cysteine S-nitrosylase activity
  directly_involved_in:
  - id: GO:0006915
    label: apoptotic process
  locations:
  - id: GO:0005634
    label: nucleus
  description: Moonlighting nuclear function - S-nitrosylates target proteins to regulate apoptosis
  supported_by:
  - reference_id: PMID:28404743
    supporting_text: GAPDH translocates to nucleus and S-nitrosylates nuclear proteins
- molecular_function:
    id: GO:0003723
    label: RNA binding
  directly_involved_in:
  - id: GO:0017148
    label: negative regulation of translation
  locations:
  - id: GO:0097452
    label: GAIT complex
  description: Moonlighting GAIT complex function - regulates inflammatory mRNA translation
  supported_by:
  - reference_id: PMID:23071094
    supporting_text: GAPDH is a component of GAIT complex that regulates translation
- molecular_function:
    id: GO:0019828
    label: aspartic-type endopeptidase inhibitor activity
  directly_involved_in:
  - id: GO:0050832
    label: defense response to fungus
  locations:
  - id: GO:0070062
    label: extracellular exosome
  description: Moonlighting antimicrobial function - secreted GAPDH has antifungal activity
  supported_by:
  - reference_id: PMID:22832495
    supporting_text: GAPDH peptide has antimicrobial activity against fungi
tags:
- lbnl-favorites
status: COMPLETE

GAPDH

Gene Description

Existing Annotations Review

Core Functions

Primary glycolytic function - catalyzes oxidative phosphorylation of G3P to 1,3-BPG

Moonlighting nuclear function - S-nitrosylates target proteins to regulate apoptosis

Moonlighting GAIT complex function - regulates inflammatory mRNA translation

Moonlighting antimicrobial function - secreted GAPDH has antifungal activity

References

Tags

📚 Additional Documentation

Deep Research Bioreason

BioReason Chat Export

Thinking Trace

Functional Summary

UniProt Summary

InterPro Domains

GO Terms

Deep Research Bioreason Rl

BioReason Chat Export

Thinking Trace

Functional Summary

UniProt Summary

InterPro Domains

GO Terms

Deep Research Perplexity

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

Target Gene/Protein Identity (from UniProt):

MANDATORY VERIFICATION STEPS:

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

Research Target:

Output

Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH): A Multifunctional Enzyme Integrating Metabolism, Signaling, and Cellular Homeostasis

Structural Organization and Oligomerization State

Primary Metabolic Function: Glycolytic Catalysis

Catalytic Mechanism: Covalent and General Acid-Base Catalysis

Non-Metabolic Functions and Moonlighting Activities

Nuclear Translocation and Apoptosis Regulation

Metabolic Switching and the GAPDH Redox Switch

Heme Metabolism and Chaperone Functions

RNA Binding and Post-Transcriptional Gene Regulation

Endoplasmic Reticulum-to-Golgi Vesicular Transport

Telomere Homeostasis and Cell Aging

DNA Damage Sensing and Repair Functions

Post-Translational Modifications and Regulation

S-Nitrosylation and Oxidative Modifications

Phosphorylation and Acetylalanylation

O-linked N-acetylglucosaminylation

Subcellular Localization and Compartmentalization

Regulation by Calcium Signaling and Metabolic State

Disease Pathophysiology and Clinical Significance

Cancer and GAPDH Upregulation

Neurodegenerative Diseases and Nuclear GAPDH Accumulation

Diabetes Mellitus and Vascular Complications

Infectious Diseases and Viral Resistance

Therapeutic Potential and Drug Development

Conclusion

Citations

Notes

GAPDH Gene Review Notes

Colleague Question

Key Findings

Canonical Function

Moonlighting Functions Confirmed

Why GAPDH is THE Moonlighting Exemplar

GO Annotation Review

Key Publications

Remaining Questions

Clinical Significance

Bioreason Rl Review

BioReason-Pro RL Review: GAPDH (human)

Functional Summary Review

Notes on thinking trace

Falcon Research

Falcon Research Report: GAPDH (HUMAN)

📄 View Raw YAML